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over-the-counter), level of potential abuse, 
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by Hugo Koch, Division of Health Care Statistics 
Introduction 
If mortality rates for certain diseasesprevailed 
today as they did at the turn of the century,
almost 400,000 Americans would lose their 
lives this year to tuberculosis, almost 300,000 
to gastroenteritis, 80,000 to diphtheria, and 
55,000 to poliomyelitis. Instead, the combined 
toll of all four diseases is projected to be less 
than 10,000 lives. That the toll is 10,000 in-
stead of 835,000 is largely due tomedicines. . . . 
The curative revolution is, in essence, a drug 
revolution.1 
With so much popular attention currently being 
directed to the tragic misuseof drugs, there is sometimes 
a tendency to forget the overwhelming benefits that 
result from their rational use, and the vital role that they 
play in the prevention, diagnosis, and treatment of dis­
ease.The purpose of this report is to describe this role in 
one treatment setting-a setting that often does not 
receive its proper share of attention-the doctor’s office. 
To accomplish this task, the report usesthe findings 
of the National Ambulatory Medical Care Survey for 
calendar 1980. Each year since 1973 the National 
Center for Health Statisticshas usedthe National Ambu­
latory Medical Care Survey (NAMCS) to collect des­
criptive data about the medical care provided in the 
doctor’s office. NAMCS data collectors contact arepre­
sentative sample of the Nation’s doctors of medicine 
and osteopathy whose primary professional effort lies in 
office-based, patient care practice. The sampled physi­
cians in turn complete records (figure 1, Patient Record) 
for a systematic random sample of their office visits over 
a weekly reporting period. When the sampled findings 
for 1980 were expanded to approximate the national 
universe of office visits, the result was an estimated 
575,745,OOO visits. A summary of general NAMCS 
findings, based on these 575.7 million office visits, has 
beeygublished.2 
e year 1980 was the first in the 8-year history of 
NAMCS that the respondents reported the number and 
names of the specific drugs-thatthey used. On the collec­
tion instrument (figure 1, item 11) four spaces were 
allowed for drugs associatedwith the principal diagnosis 
and an additional four spaces for drugs used “for all 
other reasons.” Physicians responded with an estimated 
679,593,OOOmentions of pharmaceutical agentsordered 
or provided-by any route of administration-for the 
purpose of prevention, diagnosis,or treatment. Mentions 
included immunizing and desensitizing agents and non-
prescription as well asprescription drugs. Along with all 
new drugs, the physician also recorded continued medi­
cations if the patient was specifically instructed during 
the visit to continue the medication. The methodology 
used to collect, classify, and process drug information 
for the 1980 NAMCS is reported elsewhere.3 
It should be emphasizedfrom the outsetthat NAMCS 
drug findings are designed to measure utilization-that 
is, the ordering or providing of medications (drugs) in a 
given treatment setting-the doctor’s office. They are 
not intended to serve as a market barometer. In the few 
places in this report where trade names appear, they are 
used only to illustrate patterns of utilization; their appear­
ance does not imply endorsement by the Public Health 
Service or the U.S. Department of Health and Human 
Services. Further, the term utilization does not extend 
beyond the ordering or providing of a drug in the physi­
cian’s office. Ultimate utilization of a drug depends on 
the patient’s compliance with the doctor’s instruction 
and cannot be determined from NAMCS findings. 
In the pages that follow, the 1980 findings on drug
utilization will be presented in two sections: 
Section I. 	 General patterns of drug utilization, by 
diagnosis, patient, physician, and other 
visit characteristics. 
Section II. 	 Dimensions of the drugs utilized, namely: 
entry choice (generic or brand name), pre­
scription status (prescription or nonpre­
scription), level of potential abuse, and 
composition status (single-ingredient or 
combination), by patient, physician, and 
visit characteristics. 
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ADMITTO HOSPITAL . 
.1 . 
Data users are urged to review the two appendixes to 
this report:They provide information necessary for the 
proper understanding and interpretation of the statistics 
presented. Appendix I contains a general description of 
the survey methods, sample design, and data collection 
and processing procedures. Imputation methods, esti­
mation techniques, and estimates of sampling variation 
are also presented. Since the statistics in the report are 
based on a sample of ambulatory visits rather than on all 
visits, they are subject to sampling errors. Therefore, 
particular attention should be paid to the section in 
appendix I entitled “Reliability of estimates.” Appen­
dix II presents defmitions of the terms used in this report 
and in the survey-operations.
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Section I. General patterns 
of off ice- based drug utilization 
The survey findings presentedin this section explore 
general patterns of drug utilization in the doctor’s office. 
Several terms used in this general evaluation require 
clarification at the outset. 
The term drug is interchangeable with the term 
medication. 
Adrug mention is the physician’s entry of a pharma­
ceutical agent ordered or provided-by any route of 
administration-for the purposeofprevention, diagnosis, 
or treatment. Mentions include immunizing and desensi­
tizing agents,and nonprescription as well asprescription 
drugs. Along with all new drugs, the physician also 
recorded continued medication if the patient was specif­
ically instructed during the visit to continue the medica­
tion. An estimated 679,593,OOOdrug mentions resulted 
from the 1980 survey.
A drug visit is an office visit at which one or more 
drugs were ordered or provided. In 1980 there were an 
estimated 363,489,OOOdrug visits, comprising 63 per-
cent of the total 575,745,OOOoffice visits. The percent 
of office visits represented by the drug visits will some-
times be called the drug visitproportion. 
.The drug mention rate is the average number of 
drugs utilized per office visit, obtained by dividing
the number of drug mentions by the number of office 
visits. Its magnitude is therefore influenced by the 
number of offtce visits where no drug was utilized. For 
the entire universe of 575,745,OOO office visits, the 
overall drug mention rate was 1.18 drugs per average 
office visit. 
The drug intensity rate is the average number of 
drugs utilized per drug visit, obtained by dividing the 
number of drug mentions by the number of drug visits. 
This index of utilization is especially useful when 
it, is desired to ignore the non-drug visits and to focus 
on the sheer volume of the drug therapy given, along 
with its potentials for drug-drug interactions. For the 
entire 363,489,OOO drug visits, the intensity rate 
was 1.87 drugs ordered or provided per average drug
visit. 
Overview 
Table 1 offers the data user an alphabetized listing 
of the 100 agentsmost frequently utilized by physicians 
in office practice. The listed drugs arc ‘in the form’of 
generic substances. Their frequency of mention com­
bines their mentions as single-entity agents with their 
mentions as ingredients of combination products;Thus, 
the 26,334,OOO total mentions of the ranking generic 
substance, hydrochlorothiazide, include 1$,6.04,000 
mentions of hydrochlorothiazide as a single-entity drug 
and its 14,730,OOOmentions as an ingredient of a com­
bination product. An earlier publication borrows’from 
the 1980 NAMCS findings, to list the, 200 $rand or 
generic names most frequently entered by respondirig 
physicians.4
A second useful overview of office-based drug utili­
zation appears in table 2. Here, the total 679,593,OOO 
drug mentions are described by the chief therapeutic 
effect that each was intended to produce. A comprehen: 
sive listing of 68 therapeutic categoriks is used.s.,The 
therapeutic categories were selectedfrom the American 
Hospital Formulary Classification System, copyright
American Society of Hospital Pharmacists,(reproduced 
with the Society’s permission). Table A,recaps the 16 
major therapeutic groupings according to their relative 
prominence of mention. The data user may ‘note the 
obvious preeminenceenjoyed by nontopical anti-infective 
agents and by central nervous system drugs. Together
they accounted for 32 percent of all drug,mentions. 
Diagnosis 
Proper evaluation of the patterns of drug utilization 
requires that the data user look first to the diseasesthat 
the drugs were intended to prevent, diagnose, or’cure. 
The most direct and frequent linkage. occurs here. A 
drug is seldom ifever utilized for the sole reasonhat the 
patient is over 65, or a female; or that the physician is an 
4 
Table A. Number and percent distribution of all drug mentions by 
major therapeutic categories: United States, 1980 
Number Percent 
in thousands 
All categories.. . . . . . . . . . . . . . _. . . . . . . 679,593 1100.0 
Antihistamine drugs. . . . . . . . . . . . . . . _ . . . . 43,939 6.5 
Anti-infective agents (nontopical). . . . . . . . 104,898 15.4 
Antineoplastic agents . . . . . . . . . . . . . . . . . 5,371 0.8 
Autonomic drugs.. . . . . . . . . . . . . . . . . . . . . 25.237 3.7 
Blood formation and coagulation . . . . . _ . . . 8,312 1.2 
Cardiovascular drugs.. . . . . . . . . . . . . . . . . . 64,463 9.5 
Central nervous system drugs.. . . . . . . . . . 1 10,706 16.3 
Electrolyfic. caloric, and water balance . . . . 51 a956 7.6 
Expectorants and cough preparations . . . . . 18,899 2.8 
Eye, ear, nose, and throat preparations . . . 26,076 3.8 
Gastrointestinal drugs. . . . . . . . . . . . . . _ . . . 24,140 3.6 
Hormones and synthetic substances.. . . 55,843 8.2 
Serums, toxoids, and vaccines.. . . . . . . . . . 23.711 3.5 
Skin and mucous membrane preparations.. . 55,188 8.1 
Spasmolytic agents.. . . . . , . . . . . . . . . . . . . 11,541 1.7 
Vitamins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24,244 3.6 
Residual (otheragentsand therapeutic effect 
undetermined) . . . . . . . . *. . . . . . . . . . . . . 25,068 3.7 
Major therapeutic categories’ of mentions distribution 
’ Based on the pharmacologic-therapeutic classification of the American Society of Hos­
pital Pharmacists: selected categories reproduced with the Society’s permission. 
internist, or a pediatrician. When variations in the rhythm
of utilization occur, they usually reflect differing patterns 
of morbidity. . 
It is fundamental then to examine drug utilization in 
terms of the diagnoses’rendered in office-based care. 
Table 3 makes this exploration, using the drug mentions 
specific to the first-listed (principal) diagnosis associated 
with each office visit (figure 1, item 1 la). It is readily
evident that two major diagnostic categories-respiratory 
diseaseand circulatory disease-dominate the world of 
office-based ambulatory care. Their dominance appears 
in the number of office visits in which they figure as a 
principal diagnosis; it also can be seen in most of the 
various measures of drug utilization ‘associated with 
their treatment. For example: 
Respiratory and circulatory diseaseslead other ma­
jor diagnostic categories in the proportion of their 
office visits at which one or more drugs was given 
(about 89 percent for respiratory disease and 79 
percent for circulatory.) 
The two disease groups also command the highest 
proportions of total drug mentions (about 20 percent 
for respiratory diseaseand 15 percent for circulatory). 
W ith about 1.6 drug mentions for each category per 
average office visit, they outrank the other major 
disease categories in drug mention rate. 
In its drug intensity rate, the circulatory disease 
category clearly outranks all others; for example, 
chronic,ischemic heart disease, with 2.4 drug men­
tions per average drug visit, dramatically exceeds 
the other disease categories or specific diseases 
within those categories. 
Drug utilization by diagnosis has received detailed 
attention in two reports based on the 1980 NAMCS 
findings.%6Therefore, it will not undergo extensive anal­
ysis in this general report. 
Patient 
Tables 4-8 examine the manner in which drug utiliza­
tion varies with selected characteristics of the office 
patient. (An earlier report has used advance findings of 
the 1980 NAMCS to highlight variations in utilization 
based on the age and sex of the patient.)7
Table 4, with its application of drug mention and 
intensity rates, reveals two peaks occurring along the 
spectrum of patient age-a minor.peak at the youngest 
end and a major peak at the oldest. The provision of 
prophylactic immunizations helps to explain the minor 
peak. But the most arresting fact emerging from the age 
findings is the steep increase in average drug utilization 
beginning with age 45 and reaching its highest point at 
65 years and over. Higher rates in this group, of course, 
signalthe onset-and sometimesconcomitant presence-
of the chronic, debilitating diseasesthat afflict the aging. 
Table 5 measures drug utilization from another per­
spective. Here the differences between the age groups 
are described in terms of the therapeutic effects that the 
drugs were intended to produce. Note especially the 
dramatic increase in the utilization of the diuretics and 
cardiovascular drugs that begins with age 45 years and 
continues beyond age 64. More than any other category 
of drugs, these agents contribute chiefly to the peak in 
average utilization that characterizes the oldest age 
group.
Not all the therapeutic categories, however, show 
similar increases in drug utilization with advancing age. 
Figure 2 graphically shows varying patterns by the three 
most-mentioned categories-cardiovascular drugs, cen­
tral nervous system drugs, and systemic anti-infectives. 
In direct contrast with the cardiovascular category, the 
anti-infectives are most frequently utilized by the age 
group under 25 years; their usagethen falls away abruptly
in an inverse relationship to advancing years. The use of 
the central nervous system drugs increases sharply be-
tween ages25-44 years, then subsidesgradually through-
out the later years of life. 
The relationship between the sex of the patient and 
drug utilization requires careful evaluation. 
The findings in table 4 supply the general framework 
for this evaluation. If simple volume of utilization is the 
desired criterion, then-depending on the degree of 
precision required-the data user may count the number 
of drug visits or drug mentions. When this simple enumer­
ation is applied to a study of sex differences, it becomes 
readily apparent that drug visits or mentions for female 
patients substantially outnumbered drug visits or men­
tions for males. The ratio of about 6 to 4 in favor of 
female patients closely parallels the ratio for office visits 
in general. However, when drug utilization by the sexes 
5 
- Anti-infective agent 
mm.... Cardiovasculardrugs 
- - Central nervous system drugs 
25.0 
Under 15-24 25-44 45-64 65 years 
15 years years years years and over 
Age of patient 
Figure 2. Utilization of three therapeutic categories of drugs by age of 
patient, based on percent of drug mentionswithin respective age groups: 
United States, 1980 
is viewed from other perspectives, especially those of 
averageusage,a different picture emerges-for example, 
the respectivedrug visit proportions. For female patients, 
the drug visit proportion was 63.3 percent, for male 
patients 62.8. The difference is not statistically sig­
nificant; it could be due to sampling error or variability. 
In terms of the drug mention rates or drug intensity 
rates, there is also no marked difference between the 
averagefemale and male patient. In fact, if the mentions 
of prenatal multivitamins, estrogens, and oral contra­
ceptives-agents unique to female use-are subtracted 
from the female total of drug mentions, the drug mention 
rate for the average female patient is reduced to 1.14, 
suggesting an even closer agreement in average drug 
use. 
This near equivalence in average drug utilization 
prevails up to age 65 (table 4 and figure 3). Beyond that 
point the utilization paths for the sexes diverge percep­
tibly, an effect probably due to a more intensive female 
use of the central nervous system drugs-chiefly, anal­
gesics, psychotherapeutic agents, sedatives, and hyp­
notics (table 7).
Thus the generalindexesof averageutilization seldom 
reveal any marked differences between men and women. 
Proceeding to a more specific level, tables 6 and 7 
explore sex variations in the utilization of selected ther­
apeutic groups of drugs. A comparison of the sexes 
reveals that female patients exceeded male patients in 
6 
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IAverage number of drugs ordered or provided per office visit.: 
Figure 3. Drug mention rate by sex and age of patient United States, 1980 
the proportion of their drug mentions representedby the 
following therapeutic categories: 
l Antineoplastic agents. .,I 
l 	 Central nervous system drugs (however, the use of 
analgesics, anticonvulsants, and tranquilizers was 
roughly equivalent between the sexes). 
l Electrolytic, caloric, and water balance substances. 
l 	 Hormones and synthetic substalices(however, there 
was no difference in the use of adrenals and of 
antidiabetic agents between the sexes). ‘.’ 
0 Vitamins. 
Male patients exceeded female patients in their utiliza­
tion of: 
l Antihistamine drugs. ,’ 
l Anti-infective agents. 
l 	 Cardiovascular drugs (except hypotensives, used 
about equally by both sexes). 
l Serums, toxoids, and vaccines. 
l Spasmolytic agents. 
In the utilization of the following drug categories, there 
was either no difference between male and female pro-
portions or the difference was so slight that much of it 
may be explained by the presence of sampling error. 
l Autonomic drugs. 
l Blood formation and coagulation agents (females 
made more use of anti-anemia drugs; males made 
more use of anticoagulants). 
l Gastrointestinal drugs. 
l Expectorants and cough preparations. 
l Eye, ear, nose, and throat preparations. 
l Skin preparations. 
By listing the 10 generic substances(in singlsingre­
dient plus combination ‘form) most frequently utilized 
by each sex-agegroup, table 8 shows a final perspective
of utilization as it varied with patient age and sex. 
Table 4 provides general indexes of drug utilization 
for three categories of race: white, black, and “other,” 
which chiefly includes American Indians and patients 
of Asian or Pacific Island origin. For the “other” cate­
gory, drug utilization deservesthe attention of the ana­
lyst. Although their drug visit proportion is about equiv­
alent to the proportion for white patients, their indexes 
of averagedrug utilization, as expressedin drug mention 
and intensity rates, are somewhat lower than those of 
the white or black patients, It is not in the scope of this 
general report to explore all the reasons for these lower 
rates, but the explanation seemsto lie partly in the fact 
.that 75 percent of these “other” visits were made by 
patients under 45 years of age. For black visits, the 
contrasting proportion was 65 percent; for white visits, 
a relatively modest 5 9 percent. Sincethe “other” patients 
were more youthful, their visits were less frequently 
involved with such drug-intensive conditions as Circu­
latory disease.In fact, Circulatory diseaseas a principal 
diagnosis appeared in only 4 percent of their visits 
compared with 9 percent for white visits. 
Except that black patients showed a slightly higher 
drug visit proportion, the findings in table 4 reveal no 
marked difference between white and black visits in 
average, overall drug utilization. Nor were there many 
marked differences in their respective utilization of the 
specific drug categories (table 9). For the following
major therapeutic groups, the differences were so slight 
that they were probably due in large part to the presence













Electrolytic, caloric, and water balance agents. 

Expectorants and cough preparations. 





Sedatives and hypnotics. 

Serums, toxoids, and vaccines. 

0 Spasmolytic agents. 
0 Vitamins. 
White patients significantly exceeded black patients in 
only three of the categories-antineoplastic agents,psy­
chotherapeutic agents, and skin preparations. Black 
patients exceeded white patients. only in their use of 
analgesics, hypotensives, and antidiabetic agents. 
Physician 
Drug utilization, as it varies with physician charac­
teristics, will receive detailed attention in a separate 
seriesof NAMCS reports.8Therefore, it will not undergo 
extensive exploration in these pages. 
Table 10 directs attention to the physicians who 
order or provide the drugs utilized in offrce practice, by 
providing general indexes of drug utilization according 
to the physician’s specialty, geographic region of prac­
tice, type of practice, and age. 
Note the considerable variation that exists among 
the individual specialties in the frequency and intensity
of their drug utilization. Drug visit proportions, for ex-
ample, range from a high of 76.9 percent for dermai 
tologists to a low of 29.6 percent for orthopedic sur­
geons.Drug intensity rates range from a high of 2.44 for 
cardiovascular specialists to a low of 1.28 for urolo­
gists. The variation in drug mention rates is graphically 
displayed in figure 4. 
In sheer volume of utilization, however, it is the 
general or family practitioner who clearly dominates the 
scene. With 41 percent of the total 679,593,OOOmen­
tions, this physician led all other specialities (table lo), 
maintaining this dominance throughout 12 of the 16 
major drug categories (table B). 
Table 10 reports several other findings that are 
worthy of note. Regardless of the measure of utilization 
applied, the following contrasts emerge sharply enough 
to warrant further exploration in separate NAMCS 
reports: 
l 	 The West Region fell substantially below the other 
geographic areas. 
0 	 Solo practitioners utilized drugs more frequently 
and intensively than their counterparts in multiple 
member practice. 
l 	 Physicians under 45 years of age were less likely to 
resort to drug therapy than older physicians. j 
Other visit characteristics 
Table 11 applies the familiar indexes of drug utiliza­
tion to various other dimensions of the office visit.‘Cer­
tain of the findings are highlighted below. Some point 
the way to more detailed analysis. 
An examination of drug visit proportions reveals 
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Figure 4. Drug mention rate by specialty: United States, 1980 
.I ,I. 
therapy than the patient whom the doctor has seen a newproblem-whether it is a problem presented by a 
before. This is especially true if the new patient has been new patient or a problem not encountered before in an 
referred by another physician. If one or more drugs are old patient-will probably result in fewer drugs ordered 
utilized, however, the drug intensity rates suggest that or provided,. Thus newness of patient or problem (or 
Table B. Number of mentions of major drug categories by physician specialty with the largest fraction of mentions for each category: United States, 1980’ 
,, 




Allcategories.............................................................. 679,593 General and family practice (41 .I percent)’ 
Antihistamine drugs. . . . . . . 43,939 General and family practice (46.6 percent) 
Anti-infective agents (nontopical). 104,898 General and family practice (44.9 percent) 
Antineoplastic agents . 5,371 Internal medicine (85.0 percent) 
Autonomic drugs 25,237 General and family practice (54.3 percent) 
Blood formation and coagulation 8,312 General and family practice (52.3 percent) 
Cardiovascular drugs ...... 64,463 General and family practice (46.4.pement) 
Central nervous system drugs.. ...... 1 10.706 General and family practice (49.8 percent) 
Electrolytic, caloric, and water balance 51,956 General and family practice (53.2 percent) 
Expectorants and cough preparations. . . . . 18,899 General and family practice (51.4 percent) 
Eye, ear, nose, and throat preparations 26,076 Ophthalmologists (61;2 percent) 
Gastrointestinal drugs I . . . .  ...... 24,140 General and family practice (58.2 percent) 
Hormones and synthetic substances ...... 55,843 General and family practice (44.1 percent) 
Serums, toxoids, and vaccines ...... 23,71 1 Pediatrics (56.9 percent) 
Skin and mucous membrane preparations ...... 55,168 Dermatology (46.1 percent) 
Spasmolytic agents . . . . . ...... 11,541 General and family practice (48.9 percent) 
Vitamins 24,244 General and family practice (50.4 percent) 
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both) seems to invite a more conservative approach to 
drug therapy. 
Does the use of drug therapy tend to preclude the use 
of other treatment mechanisms? The answer depends 
directly on the specific condition being treated. Detailed 
analysisby diagnosisis required. However, the evidence 
presented in table 11 does point up the fact that drug 
therapy was the only form of treatment utilized in the 
majority (54 percent) of the 363,489,OOO drug visits. 
The data on visit disposition sho;w.that drugs are 
more frequently and ‘intensely utilized when a followup 
ofsome kind has been ordered by the doctor. In fact,,the 
intensity of the drug therapy may to some extent deter-
mine the specificity of the followup instruction. Thus a 
scheduled return visit is associatedwith a drug intensity 
rate of 1.97, a planned telephone contact with an inten­
sity rate of 1.89, and the least specific “return if needed” 
with the relatively low rate of 1.78. 
Does the utilization of drugs substitute for time 
spent in face-to-face contact with the physician? The 
drug intensity rates for visit duration suggest that the 
opposite is true. They vary in direct proportion to the 
encounter time between physician and patient, from a 
low of 1.40 for drug visits that involved no face-t-face 
contact to a high of 2.03 for drug visits that exceeded 15 
minutes in the duration of encounter time. 
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Section I I. Key drug dimensions 
In this section, attention is focused on four key 
characteristics of the drug products used in 1980 of­
fice practice: 
l Their entry status: generic or brand name? 
a 	 Their prescription status: prescription (I$) or over-
the-counter (OTC)? 
l 	 Their Federal controlstatus: level of potential abuse 
or dependence. 
l 	 Their composition status: single-ingredient or com­
bination? 
Table 12 summarizes the overall distribution of 
these drug variables. 
Table 17 describes their utilization according to the 
major therapeutic categories of drugs. 
Tables 18-20 show the degree to which the drug 
dimensions varied with different diagnoses, patients, 
and physicians. 
Tables 13- 16 use the names of specific products to 
list the generic entries, nonprescription drugs, controlled 
drugs, and combination agentsmost frequently utilized. 
Entry status 
The NAMCS drug data base permits the description 
of drug mentions by their entry status, that is, whether 
the doctor recorded the medication by brand name or by 
generic name. (NAMCS respondents were instructed 
to use the same form of entry on the NAMCS visit 
record that they used on the patient’s medical record 
and on any prescription written.) 
During the past decade, extensive interest has cen­
tered on the merits of prescribing by brand-name drug 
versus prescribing by the (usually) less costly generic 
drug. Since 1970, the generic drug business has grown
faster than the total pharmaceutical market. By 1980, 
about 15 percent of all new prescriptions were written 
generically.
It should be emphasized that the extent of generic 
utilization revealed by the NAMCS data in table 12 
(24.2 percent of all drugs mentioned) reflects the total 
utilization of generic drugs in one treatment setting-
the doctor’s office. Thus, along with generically written 
prescriptions (new ones or refills), the NAMCS generic 
fraction includes nonprescription generics (for exam­
ple, aspirin or insulin); most serums, toxoids, and vac­
cines(for example, diphtheria tetanus toxoid pertussis); 
many diagnostic agents(for example, tuberculin); and a 
substantial number of other agents (chiefly the anti-
biotic injectibles) administered in the doctor’s office. 
Table 13 lists the 38 genericsmost frequently entered 
by office-based physicians. 
Of the major drug groups, the following exceeded 
the overall average in the proportion of their mentions 
that were generically identified (table 17): 
a Anti-infective agents. 
l Antineoplastic agents. 
l Serums, toxoids, and vaccines. 
0 Vitamins. 
Of the major diagnostic groups, the following were 
significantly above average in the proportion of generic 
agents applied to their treatment (table 18): 
l Neoplasms. 
l 	 Endocrine, nutritional, and metabolic diseasesand 
immunity disorders. 
l Diseases,of blood and blood-forming organs. 
l Health supervision of infant or child. 
Prescription status 
Drugs are subdividedinto two major classifications-
prescription (legend or I$) and nonprescription (over-
the-counter or OTC) drugs.The use of a prescription drug 
represents the judgment of a physician about a patient’s 
medical care needs.The use of an over-the-counter drug 
represents a much greater reliance on self-care by the 
patient. In many cases there are also significant cost 
differences between prescription and nonprescription 
10 
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drugs used for the same purpose, for example, aspirin or 
Darvon used for analgesic effect. Furthermore, some 
over-the-counter drugs are extremely important in med­
ical care (for example, aspirin for fever, insulin for 
diabetes, antacids for peptic ulcer). For these reasons 
the NAMCS drug data base distinguishes between pre­
scription and nonprescription drugs. 
Nonprescription drugs accounted for 85,344,OOO 
(12.6 percent) ofthe 679,593,OOOdrug mentions (table 
12). Table 14 lists the 30 nonprescription drugs most 
frequently utilized in office-based drug therapy. 
Of the major drug groups, the following significantly
exceededthe overall average in their proportion of non-
prescription drug mentions (table 17): 
l Blood formation and coagulation substances. 
l 	 Central nervous system drugs (chiefly the analge­
sics). 
l Expectorants and cough preparations. 
l Eye, ear, nose, and throat preparations. 
l Gastrointestinal drugs. 
l Skin and mucous membrane preparations. 
0 Vitamins. 
Of the major diagnostic groups, the following were 
significantly above average in the proportion of nonpre­
scription drugs applied to their treatment (table 18): 
l Infectious and parasitic diseases. 
l 	 Endocrine, nutritional, and metabolic diseasesand 
immunity disorders. 
l Diseases of blood and blood-forming organs. 
l Acute upper respiratory infections. 
l Diseases of digestive system. 
l Symptoms, signs, and ill-defined conditions. 
a Normal pregnancy. 
Federal control status 
A very important issue in health and social policy
is the use of medications having significant potential for 
addiction or habituation. Such medications are under 
the regulatory control of the Drug Enforcement Admin­
istration (DEA), an agency of the U.S. Department of 
Justice. In table 12, the medications used in office prac­
tice are characterized by their DEA control category 
(Schedule). Each successiveSchedule, from II through 
V, reflects a decreasing potential for abuse, as follows: 
l 	 ScheduleII (morphine, amphetamine, and so forth.)
High potential for abuse. Abuse may lead to severe 
psychological or physical dependence. 
l 	 Schedule III (paregoric, chlorphentermine, and so 
forth.) Potential for abuselessthan for drugsin Sched­
ule II. Abuse may lead to moderate or low physical
dependence or high psychological dependence. 
ScheduleIV (diazepam, phenobarbital, and so forth.) 
Potential for abuse less than for drugs in Schedule 
III. 	 Abuse may lead to limited physical or psycho 
logical dependence. 
Schedule V (Lomotil, Donnagel-PG, and so forth.)
Potential for abuse and dependence less than for 
drugs in Schedule IV. 
NAMCS data in table 12 reveal that a small, but 
critical, proportion (8.6 percent) of all drug mentions 
were controlled drugs, with drugs in Schedule IV show­
ing the highest frequency of mention. 
Table .I5 lists the 20 con$rolleddrugs most frequently 
utilized by office-based physicians. 
All except a handful of controlled drugs belonged in 
three therapeutic categories (table 17): 
l 	 Central nervous system drugs (accounted for nearly 
80 percent of all controlled mentions). 
l Expectorants and cough preparations. 
l Gastrointestinal drugs (chiefly, antidiarrhea agents). 
Of the diagnoses encountered in office practice, the 
following were significantly above average in the pro 




l Mental disorders. 

l Diseases of central nervous system. 

l Diseases of digestive system. 

l Diseases of musculoskeletal system. 

l Symptoms, signs, and ill-defined conditions. 

l Injury and poisoning. 

From the findings in table 19, it is evident that 
patient age 25-54 years was the period of life most 
frequently associated with controlled drug therapy. Fe-
male patients slightly exceededmales in their utilization 
of controlled agents, the difference being most promi­
nent in the age groups over 44 years. 
Composition status 
Table 12 revealsthat 26.4 percent ofthe 679,593,OOO 
drug mentions were combination drugs. (The propor­
tion includes the mentions of multivitamins.) An issue 
of long-standing debate in drug utilization concerns the 
use of drugs in fixed-ratio combinations as opposed to 
single-ingredient drugs. Combination drugs offer more 
potential convenience to the patient; however, they 
usually cost more and permit less flexibility in dosage 
adjustment. The NAMCS drug database allows for 
differentiating single-ingredient drugs from combina­
tion drugs and can identify the specific ingredients of the 
combinations if this information is required.
Table 16 lists the 39 combination drugs most fre-
11 
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quently utilized, along with their active ingredients and 
the therapeutic effect or effects desired. 
Of the major drug groups, 10 significantly exceeded 
the average in the proportion of their mentions repre­




Expectorants and cough preparations. 
Eye, ear, nose, and throat preparations. 
Gastrointestinal drugs. 




Of the primary diagnosesencounteredin office prac­
tice, the following were significantly above average in 
the proportion of combination drugs applied to their 
treatment (table 18): 
Diseases of eye and adnexa. 
.Otitis media. 
Acute upper respiratory infections. 1 
Diseases of digestive system. 
Diseases of genitourinary system. 
Injury and poisoning. 
Normal pregnancy (largely due to prenatal multi-
vitamins. 
Health supervision of infant or child (largely due to 
combined vaccines). 
The following specialties significantly exceededthe 
average in their utilization of combination drugs (table 
20): 
l 	 Pediatrics (largely due to the use of combined vac­
cines). 
l General surgery. 
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Table 1. Number of drug mentions and therapeutic use of the 100 generic substances most frequently utilized: United State;, 1980 ’ 
Number 
Rank 100 generic substances most frequently utilized of mentions Therapeutic we 
in thousands’ 
9 Acetaminophen ................................................... 11,990 Analgesic, antipyretic 
54 Aluminumhydroxide ............................................... 4,396 Antacid 
70 Amitriptyline.. ................................................... 3,159 Antidepressant 
13 Amoxicillin ....................................................... 11,114 Antibiotic 
12 Ampicillin ........................................................ 11,549 Antibiotic 
2 Aspirin ............................................................ 18,840 Analgesic, antipyretic 
41 Atropine ......................................................... 5.790 Anticholinergic 
57 Benzoylperoxide .................................................. 4.097 Keratolytic, acne treatment 
55 Betamethasone....................................~ .............. 4,343 Glucocorticoid 
20 Brompheniramine.....~ ........................................... 8,319 Expectorant 
27 Caffeine ......................................................... 7.031 Stimulant 
56 Cephalexin ....................................................... 4,334 Antibiotic 
59 Chlordiazepoxide .................................................. 4.057 Emotional disturbance, sedative 
81 Chlorothiazide .................................................... 2,800 Diuretic 
11 Chlorpheniramine ................................................. 11,902 Antihistaminic 
68 Chlorpropamide ................................................... 3,215 Hypoglycemic agent 
46 Chlorthalidone .................................................... 5,203 Diuretic, antihypertensive 
49 Cimetidine ....................................................... 4,852 Ulcer and gastro-intestinal disease 
75 Clindamycin ...................................................... 2,994 Antibacterial 
92 Clorazepate ...................................................... 2,383 Tranquilizer 
17 Codeine ......................................................... 9.171 Analgesic, antitussive 
48 Dexamethasone ................................................... 4,853 Anti-inflammatory 
67 Dextromethorphan ................................................. 3,268 Cough suppressant 









52 Diphenhydramine ................................................. 4,588 Antihistaminic 
98 Doxepin...~ ..................................................... 2,153 Antidepressant 
99 Ephedrine.......................: ................................ 2,122 Adrenegic (bronchodilator) 
5 Erythromycin ..................................................... 15.693 Antibiotic 
37 Estradiol ......................................................... 6.154 Estrogen replacement therapy 
80 Estrogens ........................................................ 2,854 Estrogen replacement therapy 
96 Flurazepam ....................................................... 2,202 Hypnotic 
15 Furosemide ...................................................... 10,001 Diuretic 
_, 18 Guaifenesin .................................. . ............... . ... 8,837 Cough suppressant 
61 Hydralazine ...................................................... 3,625 Antihypertensive 
1 Hydrochlorothiazide ............................................... 26,334 Diuretic 
19 Hydrocortisone ................................................... 8,654 Anti-inflammatory 
69 Hydroxyzine ....................................................... 3,209 Tranquilizer 
42 Hyoscyamine ..................................................... 5,491 Anticholinergic 
40 Ibuprofen ........................................................ 5,819 Anti-inflammatory 
66 Indomethacin ..................................................... 3,275 Anti-inflammatory 
87 lnfluenzavirusvaccine ............................................. 2,556 Immunization 
44 Insulin ................................ . ......................... 5,264 Antidiabetic 
63 Iron preparations ................................................... 3,467 Iron deficiency 
60 Isopropamideiodide ............................................... 4,013 Anticholinergic 
47 lsosorbide ....................................................... 4,957 Coronary vasodilator 
89 Levothyroxine .................................................... 2,478 Thyroid hormone 
83 Lidocaine ........................................................ 2,641 Local anesthetic 


















91 Miconazole ...................................................... 2,475 Antifungal 
25 Multivitamins general .............................................. 7,096 Vitamins 
33 Multivitamins prenatal .............................................. 6,404 Vitamins 
71 Naproxen ........................................................ 3,158 Anti-inflammatory, antipyretic, analgesic 
16 Neomycin ........................................................ 9.719 Antibiotic 
43 Nitroglycerin ..................................................... 5,452 Vasodilator 
90 Norethindrone .................................................... 2,475 Oral contraceptive 
97 Norgestrel ....................................................... 2,200 Oral contraceptive 
79 Nystatin ......................................................... 2,875 Antifungal 
3 Penicillin ........................................................ 16,937 Antibiotic 







Anticonvulsant, hypnotic, sedative 
Anorexiant 
94 Phenylbutarone .................................................. . 2,296 Anti-inflammatory 
6 Phenylephrine .................................................... 15,369 Sympathomimetic 
See footnote at e&l of table. 
15 

. . - _ l  
T a b l e  1 , N u m b e r o f d ru g  m e n ti o n s  a n d ’th e ra p e u ti c  u s e  o f th e  1 0 0  g e n e r i c  s u b s ta n c e s  m o s t fre q u e n tl y  u ti l i z e d : U n i te d  S t a te &  1 9 8 0 - C o n . 
N u m b e  r 
R a n k  1 0 0  g e n e  r i c  s u b s  ta n c e s  m o s  t fre q u e n  tl y  u ti l i z e d  o f m e n  ti d n s  
i n  th o i  /s a n d s  ’ 
4 
3 1  
2 1  
3 5  
P h e n y l p  r o p a n o l a m i n e............... 
P o l i o  v a c c i n e  . ..................... 
P o l y m i x i n  B ....................... 




1 6 1 5 6 5  
6 ,6 8 6  
7 ,7 8 4  
6 .2 7 4  
5 1  
7 6  
P o  ta s s i u m  g u a i a c o l s u l  fo n a  te ......... 
P r  e d n i s o l o n e  ...................... 
4 ,7 6 0  
2 ,9 2 4  
3 9  
8 5  
P r  e d n i s o n e  . ....................... 
P r  o c h l o  r p e  r a z i n e................... 
6 ,0 5 1  
2 ,6 0 0  
2 6  
1 4  
P r  o m e  th a z i n e  . ..................... 
P r  o p  re n o l o l  ....................... 
7 ,0 4 2  
1 0  ,3 5 1  
5 8  
8 
4 5  
7 4  
6 5  
7 8  
1 0 0  
7 7  
3 4  
9 5  
6 4  
7 
P r  o p o x y p h e n e  ..................... 
P s e u d o e p h e d  r i n e  . .................. 
R e s e  rp i n e  . ........................ 
S a l i c y l i c  a c i d  ...................... 
S c o p o l a m i n e  ...................... 
S i m e  th i c o n e  ....................... 
S o d i u m  c i  tra te ...................... 
S p i  ro n o l a c  to n e  .................... 
S u l  fa m e  th o x a z o l e  .................. 
S u l  fi s o x a z o l e...................... 
S u l i n d a c  .......................... 
T e  tra c y c l i n e  ....................... 
4 ,0 6 2  
1 2  ,3 2 1  
5 ,2 1 6  
3 ,0 4 8  
3 ,3 7 6  
2 ,8 8 4  
2 ,0 9 4  
2 ,8 8 7  
6 ,2 9 6  
2 ,2 7 5  
3 .4 4 6  
1 2  ,9 9 1  
2 4 0  
7 3  
T h e o p h y l l i n e  ...................... 
T h y  ro i d  ........................... 
6 ,7 5 0  
3 .0 7 1  
2 9  
2 3  
5 0  
5 3  
2 4  
9 3  
6 2  
T r i a m c i n o l o n e  ..................... 
T r i a m  te re n e  ....................... 
T r i p  ro l i d i n e  . ....................... 
T u b e  r c u l i n  ........................ 
V i  ta m i n  B - l  2 . . .................. 
W a rfa r i n.......................... 
Z i n c  to p i c a l  a g e n  ts ................. 
6 ,8 4 6  
7 ,6 2 6  
4 ,8 3 1  
4 ,4 8 8  
7 ,6 1 0  
2 ,3 4 0  
3 ,5 3 6  
S y m p a th o m i m e ti c  
.‘/, II 

Im m u n i z a ti o n  ., L I: . 

A n ti b a c te r i a l  ‘) 

P o ta s s i u m  re p l a c e m e n t th e ra p y  

C o u g h  p re p a ra ti o n s  / ’ : 

A n ti - i n fl a m m a to r y  “, 

A n ti - i n fl a m m a  to r y  

A n ti e m e  ti c  

A n ti h i s ta m i n e , a n ti e m e ti c , s e d a ti v e  

B e ta b l o c k e r , 

A n a l g e s i c  . 

A n ti h i s ta m i n e , c o u g h  s u p p re s s a n t I 

A n ti h y p e rte n s i v e  ‘, ‘,. .: 4 ..,Y.:: 

A n ti fu n g a l , k e ra to l y ti c  I 

H y p n o ti c , s e d a ti v e , e n ti c h o l i n e rg i c  

A n ti f l a tu l e n  t 

A n ti c o a g u l a n t : 

D i u re ti c  ,.‘. ._ ’ 

A n ti b a c te r i a l  

A n ti - i n fe c ti v e  s u l fa . 

A n a l g e s i c , a n ti p y re ti c  

A n ti b i o ti c  . 

C o ro n a r y  v a s o d i l a to r, d i u r e ti c  8 

T h y ro i d  h o rm o n e  ” 

A n ti - i n fl a m m a  to r y  

D i u re ti c  

A n  ti h i s  ta m i n i c  

T B s k i n  te s t ,; 

V i ta m i n s  

A n  ti c o a g u l a n  t 

S k i n  d i s e a s e  (a s tr i n g e n t, a n ti s e p ti c ) 

‘F re q u e n c y  o f m e n ti o n  c o m b i n e s  th e  m e n ti o n s  o f a g e n e r i c  s u b s ta n c e  a s  a s i n g l e - i n g re d i e n t a g e n t w i th i ts m e n ti o n s  a s  a n  i n g re d i e n t o f a c o m b i n a ti o n  d ru g . 
., , .  , :  .‘,,‘. 
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,-,Table 2. Number and percent distribution of drug mentions, by selected therapeutic categories: United States, 1980* 
. 
Selected tFFrap+c cat&goriesl 
All categories ............ . ............. 
Antihistamine drugs ...................... 




Penicillins ........... : .......... 
Tetracyclines ................... 
Sulfonamides ...................... 
Antineoplastic agents ..... i ............... 
Autonomic drugs ........................ 
Parasympatholytic agents .............. 
Sympathomimetic agents. ............. 
Skeletal muscle relaxants. ............ 
Blood formation and coagulation ........... 
Anti-anemia drugs ................... 
Anticoagulants ...................... 
Cardiovascular drugs. .................... 
Cardiac drugs ...................... 
Hypotensive agents ............... : .. 
Vasodilating agents ................. 
Central nervous system drugs ....... : ...... 
Analgesics and antipyretics ........... 
Anticonvulsants ....................... 
Psychotherapeutic agents ............ 
Antidepressants ................ 
Tranquilizers ................... 
Respiratory and cerebral stimulants .... 
Sedatives’ and hypnotics ............. 
Electrolytic, caloric, and water balance. ..... 
Replacement solutions. ............... 
‘Diuretics .......................... 
Expectorants and cough preparations. ...... 




of mentions Percent 






14,989 2.2 1 









. 5,820 0.86 
‘, 2;457 0.36 




















Sele+d therapeutic categories’ of mentions Percent 
in thousands distribution 
Eye, 	 ear, nose and throat preparations-Con. 
Anti-inflammatory agents ............. 




Gastrointestinal drugs ................... 
Antacids and adsorbents............. 
Antidiarrhea agents .................. 
Antiflatulents. .............. ; ....... 
Cathartics and laxatives .............. 
Emetics and anti-emetics ............. 




Gonadotropins ................ .: ... 
Insulins and antidiabetic agent ........ 
Insulins ....................... 
Thyroid and antithyroid .............. 
Serums, toxoids and vaccines ............. 
Toxoids ........................... 
Vaccines .......................... 
Skin 	 and mucous membrane preparations ... 
Anti-infectives. ..................... 
Fungicides ..................... 
Anti-inflammatory agents. ............ 
Antipruritics and local anesthetics ..... 
Emollients, demulcentsandprotectants. .. 
Keratolytic agents ................... 
Spasmolytic agents ................ _. .... 
Vitamins ............................... 
Vitamin B complex .................. 


































1 Based on the pharmacologic-therapeutic classification of the American Society of Hospital Pharmacists: selected categories reproduced with the Society’s permission. 
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Table 3. Number and percent distribution of office visits and drug mentions, number of drug visits and their percent of office visits, drug mentionrate a$d 
drug intensity rate, by major clinical problems: United States, 1980 
[Drug information is limited tc drugs ordered or provided for principal diegnosis only according to Patient Record] 
Office visits Drug visits’ Drug mentions 
Drug Drug 
Major clinical problem Number 
Percent Number Drug Number Percentin in visit in 






All major clinical problems ................ 575,745 100.0 347,536 60.4 581,231 100.0 1 .Ol 1.67 
Principal diagnosis5 
Infectious and parasitic diseases ........... 19,628 3.4 14,274 72.7 21,007 3.6 1.07 1.47 
Neoplasms ............................. 16,021 2.8 5,103 31.9 9,546 1.6 0.60 1.87 
Endocrine, nutritional, and metabolic diseases 
and immunity disorders ................. 24,166 4.2 18,064 74.7 33,240 5.7 1.38 1.84 
Diseases of endocrine glands .......... 13,558 2.4 9,986 73.7 16,523 2.9 1.22 1,.65. 
Obesity and other hyperalimentation .... 8.081 1.4 6,346 78.5 13,554 2.3 1.68 2.14. 
Diseases of blood and blood-forming organs ... 3,077 0.5 2,088 67.9 3.457 0.6 1.12 1.66 
Mental disorders ......................... 24,343 4.2 12,039 49.5 18,324 3.2 0.75 1.52 
Nonpsychotic disorders ............... 20,753 3.6 9,593 46.2 13,925 2.4 0.67 1.45 
Diseases of nervous system and sense organs ... 52,593 9.1 30,422 57.8 48,964 8.4 0.93 1.61 
Diseases of central nervous system ..... 3,722 0.6 2,932 78.8 5,413 0.9 





Otitis media (suppurative and unspeci-
fied) ............................. 11,748 2.0 10,009 85.2 17,398 3.0 1.48 1.74 
Diseases of the circulatory system .......... 53,691 9.3 42,526 79.2 84,213 14.5 1.57 1.98 
Essential hypertension ................ 25,137 4.4 21,527 85.6 38,463 6.6 1.53 1.79 
lschemic heart disease ............... 10.430 1.8 8,489 81.4 20,599 3.5 1.97 2.43’ 
Diseases of respiratory system ............. 72,886 12.7 64.718 88.8 1 16,302 20.0 1.60 1.80 
Acute upper respiratory infections ...... 15,050 2.6 13,942 92.6 26,300 4.5 1.75 1.89 
Asthma ............................ 5,921 1 .o 5,447 92.0 10,594 1.8 1.79 I.‘94 
Diseases of digestive system ............... 23,421 4.1 14,282 61 .O 24,646 4.2 1.05 1.73 
Diseases of genitourinary system ........... 32,936 5.7 19,435 59.0 26,658 4.6 0.81 1.37 
Diseases of male genital organs. ....... 4,267 0.7 2,460 57.7 3,023 0.5 0.71 1.23 
Diseases of female genital organs ...... 14,718 2.6 8,761 59.5 12,550 2.2 0.85 I.43 
Diseases of skin and subcutaneous tissue. ... 36.214 6.3 28.162 77.7 53,416 9.2 1.48 1.90 
Diseases of musculoskeletal system ......... 36,839 6.4 23,075 62.6 37,544 6.5 1.02 1,63 
Arthropathies ....................... 10,684 1.9 8,449 79.1 14,447 2.5 1.35 1.71 
Symptoms, signs, andill-definedconditions ... 19,020 3.3 10,512 55.3 17,093 2.9 0.90 1.63 
Injury and poisoning ...................... 46,187 8.0 20,227 43.8 27,264 4.7 0.59 1.35 
Normal pregnancy ....................... 26,256 4.6 8.166 31.0 9,908 1.7 0.38 1.21 
Health supervision of infant or child. ........ 17,496 3.0 9,701 55.4 15,219 2.6 0.87 1.57 
Residual ............................... 70,971 . . . . . . . . . . . . . . . . 
Problem categories 
Acute problem .......................... 208.428 36.2 147,587 70.8 241,946 41.6 1.16 1.64 
Chronic problem, routine. ................. 162,075 28.2 108,692 67.1 194,718 33.5 1.20 1.79 
Chronic problem, flareup .................. 52.703 9.2 38,303 72.7 68,903 11.9 1.31 1.80 
Post surgery/post injury ................... 50.169 8.7 11,961 23.8 18,019 3.1 0.36 1.51 
Non-illness care ......................... 102,370 17.8 40,993 40.0 57,645 9.9 0.56 1.41 
‘An office visit at which one or mere drugs were ordered or provided. 
~Percent of office visits at which one or more drugs were ordered or provided. 
The average number of drugs ordered or provided per office visit. 
4 The average number of drugs ordered or provided per drug visit. 
5Based on the international Classification of Diseases, 9rh Revision, Clinical Modification (ED-g-CM). 
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Table 4. Number and percent distribution of office visits and drug mentions, number of drug visits and their percent of office visits, drug mention rate and 
drug intensity rate, by patient characteristics: United States, 1980 
Office visits Drug visits’ Drug mentions 
Drug Drug 



















All patients ............................. 575,745 100.0 363,489 63.1 679,593 100.0 1 .'I8 1.87 
Age 
Under 5 years ........................... 56,557 9.8 38,854 68.7 65,167 9.6 1 .15 .68 
5-14years ............................. 52,799 9.2 32,910 62.3 50,476 7.5 0.96 .53 _ 
15-24 years. ........................... 81,561 14.2 46,353 56.8 75,213 11.1 0.92 .62 
25-34 years ............................ 93,167 16.2 50,889 54.6 83,802 12.4 0.90 .65 
35-44years ............................ 61,529 10.7 36,454 59.2 64,324 9.5 1.05 .76 
45-54 years ............................ 61,472 10.7 40,006 65.1 78.351 11.5 1.27 .96 
55-64years ............................ 68,173 11.8 46,320 67.9 97.221 14.3 1.43 2.10 
65-74years ............................ 60,917 10.6 43,906 72.1 98,924 14.5 1.62 2.25 
75yearsandover ........................ 39,571 6.9 27,798 70.2 66.1 15 9.7 1.67 2.38 
Sex 
Female ................................. 346,106 60.1 219.216 63.3 413,570 60.9 1.19 1.89 
Male .................................. 229,639 39.9 144,274 62.8 266,023 39.1 1.16 1.84 
Sex and age 
Female 
Under 15 years .......................... 50,503 8.8 33,395 66.1 54,723 8.1 1.08 1.64. 
15-24years ............................ 54,879 9.5 31,350 57.1 49,823 7.3 0.91 1.59 
25-44years ............................ 103,562 18.0 58.025 56.0 97,947 14.4 0.95 1.69 
45-64years ............................ 76,385 13.3 52,223 68.4 106.333 15.6 1.39 2.04 
65yearsandover ........................ 60.777 10.6 44,222 72.8 104.745 15.4 1.72 2.37 
Male 
Underl5years .......................... 58,852 10.2 38,368 65.2 60,920 9.0 1.04 1.59 
15-24 years .................... ..- ...... 26,682 4.6 15,003 56.2 25.391 3.7 0.95 1.69 
25-44 years ............................ 51,134 8.9 29,318 57.3 50.179 7.4 0.98 1.71 
45-64 years ............................. 53,260 9.3 34,105 64.0 69,239 10.2 1.30 2.03 
65 years and over ........................ 39.712 6.9 27,481 69.2 60.294 8.9 1.52 2.19 
Race 
White .................................. 516,616 89.7 324,648 62.8 608.346 89.5 1.18 1.87 
Black .................................. 52,872 9.2 34,903 66.0 64.808 9.5 1.23 1.86 
Other5 ................................. 6,257 1.1 3,938 62.9 6,439 0.9 1.03 1.64 
Ethnicity 
Hispanic ............................... 28.720 5.0 18,949 66.0 34,239 5.0 1.19 1.81 
Not Hispanic ............................ 547,025 95.0 344.540 63.0 645,354 95.0 1.18 1.87 
‘An office visit at which one or more drugs were ordered or provided. 
~Percent of office visits at which one’or more drugs were ordered or provided. 
The average number of drugs ordered or provided per office visit. 
+h e average number of drugs ordered or provided per drug visit. 
5Asian, Pacific Islander, American Indian, or Alaskan Native. 
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Table 5. Number and percent distribution of drug mentions by selected therapeutic categories, according to age of patient: United States, IS& :““: 
Age of patient 
Under 25 years 25-44 years 45-64 years 65 years and over 
_ 





















thousands thousands thousands thousands 
All categories ....................... 190,856 100.00 148,126 100.00 175.572 100.00 165,038 
Antihistamine drugs. ................. 22.710 11.90 10.61 1 7.16 6,840 3.90 3,779 2.29 
Anti-infective agents ................. 53,728 28.15 25,435 17.17 15,334 8.73 10,402 6.30 
Antibiotics. ..................... 49,068 25.70 21,351 14.41 12,308 7.01 7,353 4.46 
Cephalosporins. ............. 3,562 1.87 1,957 1.32 1,241 0.71 772 0.47 
Erythromycins ............... 8,132 4.26 3,259 2.20 2,322 1.32 1,275 0.77 
Penicillins. ................. 26,658 13.97 8,305 5.61 4,394 2.50 2,173 1.32 
Tetracyclines. ............... 6,338 3.32 5,517 3.72 3,235 1.84 2,417 1.46 
Sulfonamides ................... 3,202 1.68 1,683 1.14 1,698 0.97 1.732 1.05 
Antineoplastic agents ................ *218 *0.11 ‘672 ‘0.45 2,591 1.48 1,889 1.14 
Autonomic drugs .................... 5,537 2.90 7,273 4.91 7,275 4.14 5,153 3.12 
Parasympatholytic agents ......... 2,344 1.23 3,263 2.20 3,133 1.78 2,612 1.58 
Sympathomimetic agents ......... 2,437 1.28 1,582 1.07 1,785 1.02 I,31 1 0.79 
Skeletal muscle relaxants ......... ‘622 *0.33 2,102 1.42 1,727 0.98 *589 *0.36 
Blood formation and coagulation 1,595 0.84 1,757 1.19 2,078 1.18 2,883 1.75 
Anti-anemia drugs ............... 1,581 0.83 1,496 1 .Ol 1.080 0.62 1,663 1 .Ol 
Anticoagulants .................. 2 0.00 *241 *0.16 982 0.56 1,220 0.74 
Cardiovascular drugs ................. 794 *0.42 4,293 2.90 23,991 13.66 35,386 21.44 
Cardiac drugs ................... +450 ‘0.24 1,620 1.09 9,272 5.28 14,990 9.08 
Hypotensive agents .............. *220 ‘0.12 1,956 1.32 9,585 5.46 10,872 6.59 
Vasodilating agents .............. *110, *0.06 *557 ‘0.38 4,877 2.78 9,102 5.52 
Central nervous system drugs .......... 15,442 8.09 32,221 21.75 36,375 20.72 26,669 16.16 
Analgesics and antipyretics. ....... 9,997 5.24 14,656 9.89 18.135 10.33 IS,01 3 9.10 
Psychotherapeutic agents ......... 1,420 0.74 5,022 3.39 6,281 3.58 3,672 2.22 



















Sedatives and hypnotics .......... 2,500 1.31 7,044 4.76 8.743 4.98 6,750 4.09 
Electrolytic. caloric, and waterbalance. ... 1,845 0.97 6,839 4.62 20,485 11.67 22,787 13.81 
Replacement solutions ............ *535 ‘0.28 *702 *0.47 2,913 1.66 2,982 1.81 
Diuretics ....................... 943 0.49 5,697 3.85 16,909 9.63 19,285 11.69 
Expectorants and cough preparations. ._ 9,988 5.23 3,980 2.69 3,166 1.80 1,766 1.07 
Eye. ear, nose, and throat preparations. ... 6,969 3.65 5,128 3.46 5,756 3.28 8,223 4.98 
Anti-infectives. .................. 2,633 1.38 1,864 1.26 1,293 0.74 950 0.58 
Antibiotics. ................. 1,831 0.96 1,348 0.91 905 0.52 *663 *0.40 
Anti-inflammatory agents. ......... 919 0.48 1,052 0.71 1 ,176 0.67 1,264 28.65 
Gastrointestinal drugs ................ 4,278 2.24 5,063 3.42 7,268 4.14 7,530 4.56 
Antacids and adsorbents .......... *469 *0.25 808 0.55 1,362 0.78 1,093 0.66 
Antidiarrhea agents .............. 1,638 0.86 *753 *0.51 ‘748 0.43 *596 *0.36 
Antiflatulents ................... *353 *0.18 *669 *0.45 1,058 0.60 804 0.49 
Cathartics and laxatives. .......... *570 *0.30 ‘745 *0.50 1,069 0.61 1,372 0.83 
Emetics and antiemetics .......... 893 0.47 +740 ‘0.50 944 0.54 1,705 1.03 
Hormones and synthetic substances .... 9,566 5.01 13,883 9.37 18,335 10.44 14,060 8.52 
Adrenals ....................... 3,500 1.83 4,483 3.03 6,109 3.48 4,220 2.56 
Contraceptives .................. 4,534 2.38 3,136 2.12 *124 *0.07 z 0.00 
Estrogens ...................... *178 ‘0.09 1 ,I 38 0.77 3,694 2.10 1,123 0.68 
Insulins and antidiabetic agents., *331 *0.17 1,113 0.75 4,335 2.47 5,419 3.28 
Insulins .................... ‘263 “0.14 826 0.56 2,124 1.21 2,051 1.24 
Thyroid and antithyroid ........... *322 *0.17 1,912 1.29 2,531 1.44 2.082 1.26 
Serums, toxoids, and vaccines ......... 18,660 9.78 1,205 0.81 I ,738 0.99 2,109 1.28 
Toxoids ........................ 8,050 4.22 *603 *0.41 *527 *0.30 ‘176 *0.11 
Vaccines ....................... 10,341 5.42 ‘359 +0.24 1,093 0.62 1,861 1.13 
Skin and mucous membrane 
preparations ...................... 21,612 11.32 15,917 10.75 10,047 5.72 7,613 4.61 
Anti-infectives. .................. 5,149 2.70 3,932 2.65 1,938 1.10 1,551 0.94 
Fungicides. ................. 2,059 1.08 1,930 1.30 854 0.49 *489 ‘0.30 
Anti-inflammatory agents. ......... 7,497 3.93 6,310 4.26 5,027 2.86 3,473 2.10 
Antipruritics and local anesthetics 843 0.44 1,431 0.97 934 0.53 845 0.51 
Emollients. demulcents, and 
protectants ................... 856 0.45 993 0.67 *610 ‘0.35 ‘555 ‘0.34 
Keratolytic agents. ............... 4,769 2.50 1.705 1.15 ‘427 ‘0.24 *312 *0.19 
See footnote at end of table. 
‘ioo.bo. ’ 
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Table 5. Number and percent distribution of drug mentions by selected therapeutic categories, according,to age of patient: United States, 1980-Con. 
Age of patient 
Under 25 years 25-44 years 45-64 years 65 years and over 














thousands thousands thousands thousands 
Spasmolytic agents .................. 2,447 1.28 . 1,520 1.03 3,223 1.84 4.350 2.64 
\ Vitamins ........................... 5,807 3.04 7,214 4.87 5,179 2.95 6,043 3.66 
Vitamin B complex ............... *437 *0.23 1,502 1 .Ol 2,498 1.42 3,451 2.09 
Multivitamin preparations ......... 4,169 2.18 4,801 3.24 1,866 1.06 1,964 1.19 
1 From the pharmacologic-therapeutic classification of the American Society of Hospital Pharmacists: selected categories reproduced with the Socievs permission. 
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Table 6. Number and percent distribution of drug mentions by selected therapeutic categories, according to 	sex of patient: United States, 1980 
Sex of patient 
Female Male 











Allcategories ........................................................ 413,570 100.00 266,023 100.00 
Antihistaminedrugs .................................................. 24,580 5.94 19,360 7.28 
Anti-infective agents .................................................. 59,385 14.36 45.513 17.11 
Antibiotics ...................................................... 49,594 11.99 40,487 15.22 
Cephalosporins .............................................. 3.848 0.93 3,684 1.38 
Erythromycins ............................................... 8,026 1.94 6,963 2.62 
Penicillins.. ................................................ 22,346 5.40 19,183 7.21 
Tetracyclines ................................................ 9,938 2.40 7,568 2.84 
Sulfonamides .................................................... 4,722 1.14 3,594 1.35 
Antineoplastic agents .................................................. 4,114 0.99 1,257 0.47 
Autonomicdrugs ..................................................... 15,312 3.70 9,925 3.73 
Parasympatholytic agents .......................................... 7,107 1.72 4,245 1.60 
Sympathomimetic agents .......................................... 3,933 0.95 3,181 1.20 
Skeletal muscle relaxants .......................................... 2,914 0.70 2,127 0.80 
Blood formation and coagulation ........................................ 5,721 1.38 2,591 0.97 
Anti-anemiadrugs ................................................ ‘4,637 1.12 1,183 0.45 
Anticoagulants ................................................... 1,065 0.26 1,392 0.52 
Cardiovasculardrugs .................................................. 35,360 8.55 29,103 10.94 
Cardiacdrugs .................................................... 13,370 3.23 12,961 4.87 
Hypotensiveagents ............................................... 14,135 3.42 8,498 3.19 
Vasodilatingagents ............................................... 7,401 1.79 7,244 2.72 
Central nervous system drugs ........................................... 70,576 17.06 40,131 15.09 
Analgesics and antipyretics ........................................ 34,544 8.35 23,256 8.74 
Anticonvulsants .................................................. 1,535 0.37 1,210 0.45 
Psychotherapeuticagents .......................................... 10,817 2.62 5,578 2.10 
Antidepressants .............................................. 7,239 1.75 3,164 1.19 
Tranquilizers.. .............................................. 3,065 0.74 2,011 0.76 
Respiratory and cerebral stimulants ...................................... 6.928 1.68 1,791 0.67 
Sedativesandhypnotics ............................................... 16,746 4.05 8,290 3.12 
Electrolytic, caloric, and water balance. .................................. 33,285 8.05 8,671 7.02 
Replacement solutions ............................................ 4,589 1.11 2,543 0.96 
Diuretics ........................................................ 27.700 6.70 15,134 5.69 
Expectorants and cough preparations .................................... 10,460 2.53 8.439 3.17 










Anti-inflammatory agents., ........................................ 2,536 0.61 1,875 0.70 
Localanesthetics ................................................. 1,658 0.40 985 0.37 











Gastrointestinal drugs ................................................. 14,371 3.47 9,768 3.67 
Antacidsandadsorbents .......................................... 2,004 0.48 1,728 0.65 
Antidiarrhea agents ............................................... 2,367 0.57 1,367 0.51 
Antiflatulents. ................................................... 1,628 0.39 1,256 0.47 
Cathartics and laxatives ........................................... 2,482 0.60 1,273 0.46 
Emetics and anti-emetics .......................................... 2.817 0.68 1,465 0.55 
Hormonesandsyntheticsubstances ..................................... 41,266 9.98 14,577 5.48 
Adrenals ........................................................ 11,034 2.67 7.279 2.74 
Contraceptives ................................................... 7,807 1.89 
Estrogens ....................................................... 5,792 1.40 ‘341 ‘0.13 
Gonadotropins ................................................... 1,411 0.34 ‘257 ‘0.10 
Insulins and antidiabetic agents ..................................... 6,699 1.62 4,499 1.69 
Insulins ..................................................... 3,180 0.77 2,084 0.78 
Thyroidandantithyroid ............................................ 5,832 1.41 1 ,015 0.38 
Serums, toxoids, and vaccines .......................................... 12,154 2.94 11,557 4.34 
Toxoids ......................................................... 4,768 “1.15 4,587 1.72 
Vaccines ........................................................ 7,036 1.70 6,619 2.49 










Fungicides .................................................. 3,51 1 0.85 1,821 0.68 
Anti-inflammatory agents .......................................... 12,556 3.04 9,751 3.67 
Antipruritics and local anesthetics ................................... 2.430 0.59 1,623 0.61 
Emollients, demulcents, and protectants .............................. 1,549 0.37 1,465 0.55 
Keratolytic agents ................................................ 4,536 1 .lO 2,677 1 .Ol 
See footnote at end of table. 
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Table 6. Number and percent distribution of drug mentions by selected therapeutic categories, according to sex of patient: United States, 1980-Con, 
Sex of patient 
Female Male 
Selected therapeutic categories’ 
Number Percent Number Percent
of mentions distribution of mentions distribution
in thousands in thousands 
Spasmolyticagents ................................................... 5,809 1.40 5.732 2.15 
Vitamins ............................................................ 19,301 4.67 4,943 1.86 
Vitamin 8 complex ............................................... 5,678 1.37 2,210 0.83 
Multivitamin preparations ........................................... 10,779 2.61 2,021 0.76 




















Table 7. Number and percent distribution oi drug mentions by selected therapeutic categories, according to age and sex of patient: United States, 1980 .? ’ 
Age and sex of patient 











Selected therapeutic categories’ 
All categories ......................... 
Antihistamine drugs .................... 
Anti-infective agents (non-topical) ........ 
Antibiotics ........................ 
Antineoplastic agents .................. 
Autonomic drugs ...................... 
Blood formation and coagulation ......... 
Cardiovascular drugs ................... 
Cardiac drugs ..................... 
Hypotensive agents ................ 
Vasodilating agents ................ 
Central nervous system drugs ............ 
Analgesics and antipyretics. ......... 
Psychotherapeutic agents ........... 
Sedatives and hypnbtics ............ 
Electrolytic, caloric, and water balance .... 
Diuretics ......................... 
Expectorants and cough preparations. ..... 
Eye, ear, nose, and throat preparations .... 
Gastrointestinal drugs .................. 
Hormones and synthetic substances ...... 
Adrenals ......................... 
Insulins and antidiabetic agents ...... 
Serums. toxoids, and vaccines ........... 
Skin and mucous membrane preparations 
Anti-inflammatory agents ............ 
Spasmolytic agents ..................... 
Vitamins ............................. 










distribution of mentions 
in thousands 
,++wiio~ 
104,546 100.00 86.31 1 100.00 97.947 100.0~ 
10,713 10.25 11,998 13.90 6,878 7.02 
28,333 27.10 25,395 29.42 16,633 16.98 
25,253 24.15 23,815 27.59 13,322 13.60 
z 0.00 *166 *0.19 ‘486 ‘0.50 
2,557 2.45 2,980 3.45 4,654 4.75 
1,457 1.39 *138 *0.16 1,528 *‘Xl& 
*343 *0.33 *451 *0.52 2,103 ’ ,2.15 
‘116 +0.11 *333 *0.39 770 0.79 
‘132 *I .26 *a8 *0.10 1,022 1.04 
‘79 *0.07 Z 0.00 *227 *0.23 
8,709 8.33 6,732 7.80 20,332 20.76 
5,188 4.96 4,809 5.57 8,086 8.26 
843 0.81 *577 *0.67 3,1,31 ,3.20 
1,593 1.52 907 1.05 4,713 4.81 
1,320 1.26 *525 *0.61 4,833 4.93 
‘763 *0.73 ‘180 *0.21 4,189 4.28 
5,165 4.94 4,824 5.59 .2,226 2.27 
3,599 3.44 3,370 3.90 2,581 2..64 
2,526 2.42 1,752 2.03 2,907 .2.97 
7,498 7.17 2,067 2.39 11,274 11.51 
1,901 1.82 1,600 1.85 2,781 2.84 
‘165 ‘0.16 ‘166 *0.19 *659 *0.67 
9,206 8.81 9,454 10.95 *645 *0.66 
11,756 11.24 9,856 11.42 10,409 10.63 
3,736 3.57 3,760 4.36 3,81 7 3.90 
864 0.83 1,584 1.84 992 1 .Ol 
5,109 4.89 *699 *0.81 6,433 6.57 
Number Number Percent 

























Table 7. Number and percent distribution of drug mentions by selected therapeutic categories, accdrding to aie and sex of patient: United States, 1980-Con. 
Age and sex of patient-Con. . 
25-44 iears-Con. 45-64 years 65 years and over 







Percentof mentions Percent of mentions of mentions of mentions 
in thousands 
distribution of mentions distribution 
in thousands 
distribution in thousands distribution in thousands 
distribution
in thousands 
50,179 100.00 106,333 100.00 69,239 100.00 104.745 100.00 60,294 100.00 
3,733 7.44 4,431 4.17 2,409 3.48 2,558 2.44 1,220 2.02 
8,802 17.54 8,912 8.38 6,422 9.27 5,507 5.26 4,895 8.12 
8,030 16.00 7,188 6.76 5,120 7.39 3,831 3.66 3,522 5.84 
'186 *0.37 2,119 1.99 '472 *0.68 1,457 1.39 '432 *0.72-
2.619 5.22 4,562 4.29 2,713 3.92 3,540 3.38 1,613 2.67 
,f229 '*0.46 1,068 1 .oo 1,009 1.46 1,669 1.59 1,214 2.01 
2,190 4.36 11,432 10.75 12,559 18.14 21,483 20.51 13,903 23.06 
850 1.69 3,79.l 3.57 5,481 7.92 8,694 8.30 6,296 10.44 
934 1.86 5,579 5.25 4,006 5.79 7.402 7.07 3.470 5.76 
'330 '0.66 1,982 1.86 2,896 4.18 5,113 4.88 3,989 6.62 
11,849 23.69 23,025' 21.65 13,349 19.28 18,509 17.67 8.160 13.53 
6,570 13.09 11,033 10.38 7,101 IO.26 10.237 9.77 4,776 7.92 
1,891 3.7.7 4.027 3.79 2,254 3.26 2,815 2.69 856 1.42 
2,331 4.64 5,742 5.40 3,001 4.33 4,698 4.49 2,051 3.40 
2,006 4.00 12,525 11.78 7,960 11.50 14,607 13.95 8,179 13.57 
1,508 3.01 10,282 9.67 6,627 9.57 12,466 11.90 6,818 11.31 
1,754 3.50 2,120 1.99 1,046 1.51 951 0.91 815 1.35 
2,547 5.08 3,437 3.23 2,320 3.35 5:191 4.96 3,031 5.03 
2,156 4.30 4,136 3.89 ' 3.132 4.52 4,802 4.58 2,728 4.52 
2,609 5.20 13,201 12.41 5,134 7.41 9,292 8.87 4,768 7.91 
‘1.702 3.39 3.771 3.55 2,338 3.38 2,581 2.46 1,639 2.72 
*453 '0.90 2,468 2.32 1.867 2.70 3,407 3.25 2,012 3.34 
'560 '1.12 1,044 0.98 '693 *1.00 1,260 1.20 849 1.41 
5,508 10.98 5.807 5.46 4,240 6.12 4,515 ,4.31 3,097 5.14 
2,493 4.97 . 2.817 2.65 2.210 '3.19 2,186 2.09 1,287 2.14 
'528 1.05 1,710 1.61 1,513 2.19 2,244 2.14 2,107 3.49 
















































































































Table 8. Number of mentions snd number of mentions per 1,000 office viaita of the 10 generic substances most frequently utilized, 
by sex-age groups of patient United States, 1980 
Number of Number Number of Number 
Rank 
Sex-age group and generic mentions of mentions 
Rank 
Sex-age group and generic mentions of mentions 
substances most frequently utilized in per 7,000 substances most frequently utilized in per 1,000 
thousands office visits2 thousands? office visits2 
Female patients under 15 years 
Phenylpropanolamine. . ..’.... ., 3,833 76 
Penicillin . . . . . . . . . . . . . . . . . . . . . . . 3,511 70 
Phenylephrine. .,.,..........,.. 3,427 68 
Amoxicillin . . . . . . . . . . . . . . . . . . . . 3,359 67 
Polio vaccine ., . . . . . . . . . . . . . . . 3,178 63 
Diphtheria tetanus toxoida pertussis. . 3,028 60 
Erythromycin . . . . . . . . . . . . . . . . . . . . 
Ampicillin . . . . . . . . . . . . . . . . . . . . . . 
Brompheniramine. . . . . . . . . . . . . . . 
Chlorpheniremine. . . . . . . . . . . . . . . 
Female patienta 15-24 years 
Estradiol . . . . . . . . . . . . . . . . . . . . . . 
Multivitamin prenatal ., ., . . . . . . . 
Tetracycline . . . . . . . . . . . . . . . . . . . 
Penicillin . . . . . . . . . . . . . . . . . . . . . ,. 
Norethindrone, . . . . . . . . . . . . . . . . ,. 
Ampicillin, . . . . . . . . . . . . . . . . . . . . 
Erythromycin, . . . . . . . . . . . . . . . . . . . 
8enzoyl peroxide,.,......,.,., 
Norgestrel . . . . . . . . . . . . . . . . . . . . . . 
Aspirin ., ., ., ., . .,, ., . .,.,...,. . 
Female patients 25–44 years 
Multivitamins prenatal . . . . . ., ., . . 
Aspirin . . . . . . . . . . . . . . . . . . . . . . . 
Tetracycline . . . . . . . . . . . . . . . . . . . 
Pseudoephedrine, . . . . . . . . . . . . . . 
Penicillin . . . . . . . . . . . . . . . . . . . . . 
Erythromycin . . . . . . . . . . . . . . . . . . . . 
Acetaminophen ., . . . . . . . . . . . . . ., 
Hydrochlorothiazide, . . . . . . . . . . . 
Eatradiol . . . . . . . . . . . . . . . . . . . . . . 
Phenylpropanolam ine. . . . . . . . . . . . 
Female patients 45-64 yeers 
Hydrochlorothiazide, ., ., 
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . 
Propranolol ...,.,.,......,.,., 
Methyldopa .,.,.,.,......,.,., 
Estrogens . . . . . . . . . . . . . . . . . . . . . 
Furosemide ...,.,.,......,., .,. 
Acetaminophen .,.,........,., . . 
Triamterene. ..,.,........,., .,. 
Potasaium replacement solutions . . 
Ibuprofen . . . . . . . . . . . . . . . . . . . . . . . 
Female patienta 65 years and over 
Hydrochlorothiazide, . . . . . 
Dioxin . . . . . . . . . . . . . . . . . . . . ,,. . 
Methyldopa. . ., . . . . . . . . . . . . . . . . 
Furosemide . . . . . . . . . . . . . . . . . .,. 
Aspirin . . . . . . . . . . . . . . . . . . . . . . . 
Propranolol . . . . . . . . . . . . . . . . . . . . . 
Vitamin B-12 . . . . . . . . . . . . . . . . . . . . 
Triamterene. ..,.,.,......,.,.,.. 














































Male patients under 15 years 
Phanylephrine . . . . . . . . . . . . . . . . . . . 
Amoxicillin . . . . . . . . . . . . . . . . . . . . . 
Phenylpropanolamine. . . . . .. . . . . . . . 
Erythromycin . . . . . . . . . . . . . . . . . . . 
Penicillin . . . . . . . . . . . . . . . . . . . . . . 
Polio vaccine . . . . . . . . . . . . . . . . . . . 
Brompheniramine . . . . . . . . . . . . . . . 
Diphtheria tetanus toxoids pertuaais. 
Paeudoephedrine . . . . . . . . . . . . . . . . 
Guaifenesin . . . . . . . . . . . . . . . . . . . ,. 
Male patients 15-24 years 
Tetracycline . . . . . . . . . . . . . . . . . . . . 
Penicillin . . . . . . . . . . . . . . . . . . . . . . . 
Benzoyl peroxide . . . . . . . . . . . . . . . . 
Erythromycin . . . . . . . . . . . . . . . . . . . . 
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . 
Clindamycin . . . . . . . . . . . . . . . . 
Ampicillin . . . . . . . . . . . . . . . . . . . 
Pseudoephedrine . . . . . . . . . . . . . . . . 
Phenylpropanolamine. . . . . . . . . . . 
Acetaminophen . . . . . . . . . . . . . . . . 
Male patients 25-44 yeara 
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . 
Penicillin . . . . . . . . . . . . . . . . . . . . . . 
Acetaminophan . . . . . . .. l....... 
Tetracycline . . . . . . . . . . . . . . . . . . . 
Pseudoephedrine . . . . . . . . . . . . . . 
Erythromycin . . . . . . . . . . . . . . . . . . . . 
Chlorpheniramine . . . . . . . . . . . . . . . . 
Phenylephrine . . . . . . . . . . . . . . . . . . . 
Caffeine . . . . . . . . . . . . . . . . . . . . . . 
Phenylpropanolam ine. . . . . . . . . . 
Mala patients 45–64 years 
Hydrochlorothiazide. . . . . . . . . . . . . . 
P~opranolOl . . . . . . . . . . . . . . . . . . . . . 
Aspirin, . . . . . . . . . . . . . . . . . . . . . . . . 
Dioxin . . . . . . . . . . . . . . . . . . . . . . . . 
Triamtarene . . . . . . . . . . . . . . . . . . . . . 
Diazepam . . . . . . . . . . . . . . . . . . . . . . 
Furoaemide . . . . . . . . . . . . . . . . . . . . . 
Nitroglycerin . . . . . . . . . . . . . . . . . . . . 
Isosorbide . . . . . . . . . . . . . . . . . . . . 
Erythromycin . . . . . . . . . . . . . . . . . . . . 
Male patienta 65 years and over 
Hydrochlorothiazide. . . . . . . . . . . . . . 
Dioxin. . . . . . . . . . . . . . . . . . . . . 
Furosemide . . . . . . . . . . . . . . . . . . . . . 
Propranolol . . . . . . . . . . . . . . . . . . . . . 
Isosorbide . . . . . . . . . . . . . . . . . . . . 
Nitroglycerin . . . . . . . . . . . . . . . . . . . 
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . 
Methyldopa . . . . . . . . . . . . . . . . . . . . . 
Theophylline . . . . . . . . . . . . . . . . . . . . 

























1,334 26 i 
1,251 24 
1,088 21 























1 Fra~uencY of mention ~~mbine~ ~ha ~antio”~ of o generic substance as a single. ingredient agent with its mentions as an ingredient of a combination drug. 
2For each ~ex.age ~roUp, the number of office visits may ba obtainad from table 4. 
/ 
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Table 9. Number and percent distribution of drug mentions by selected therapeutic categories, according to race and ethnicity of patient: United States, 1980 
Race’of patient’ Ethnichy of patient 
Black White Hispanic Non-Hispanic 




















thousands thousands thousands thousands 
All categories ....................... 6480.8 100.00 608,346 100.00 34,239 100.00 645,354 100.00 
Antihistamine drugs ................... 3,565 5.50 39,924 6.56 1,602 4.68 42,337 6.56 
Anti-infective agents ................. 9,541 14.72 94,050 15.46 6,143 17.94 98,755 15.30 
Antibiotics. ..................... 8,050 12.42 80,818 13.28 5,149 15.04 84,931 13.16 
Antineoplastic agents ................ ‘254 *0.39 5,103 0.84 ‘40 *0.12 5.331 0.83 
Autonomic drugs .................... 3,130 4.83 21,844 3.59 1,551 3.71 23,686 3.67 
Blood formation and coagulation ....... 1,190 1.84 7,049 1.16 *213 0.62 8,099 1.25 
Cardiovascular drugs ................. 6,342 9.79 57.785 9.50 1,858 5.43 62,605 9.70 
Cardiac drugs ................... 2,022 3.12 24,219 3.98 *610 1.78 25,721 3.99 
Hypotensive agents .............. 3,174 4.90 19,270 3.17 ‘696 2.03 21,937 3.40 
Vasodilating agents .............. 1 ,I 01 1.70 13,487 2.22 *513 1.50 14,133 2.19 
Central nervous system drugs .......... 11,386 17.57 98,137 16.13 6,376 18.62 104.330 16.17 
Analgesics and antipyretics ........ 6,697 10.33 50,316 8.27 3,112 9.09 54,688 8.47 
Psychotherapeutic agents ......... 990 1.53 15,320 2.52 994 2.90 15,401 2.39 
Sedatives and hypnotics .......... 2,365 3.65 22,481. 3.70 1,630 4.76 23,406 3.63 
Electrolytic, caloric, and waterbalance. ... 5,608 8.65 46,009 7.56 1,677 4.90 50.279 7.79 
Diuretics ....................... 4,765 7.35 37,862 6.22 1,368 4.00 41,466 6.43 
Expectorants and cough preparations .... 2,117 3.27 16,553 2.72 1,321 3.86 17,578 2.72 
Eye. ear, nose, and throat preparations. ... 2,485 3.83 23,392 3.85 912 2.66 25,165 3.90 
Gastrointestinal drugs ................ 2,323 3.59 21,581 3.55 1,313 3.83 22,827 3.54 
Hormones and synthetic substances .... 5,854 9.03 49,503 8.14 3.097 9.05 52,746 8.17 
Adrenals ....................... 1,459 2.25 16,757 2.75 780 2.28 17.532 2.72 
Insulins and antidiabetic agents .... 1,864 2.88 9,117 1.50 *712 2.08 10,486 1.62 
Serums, toxoids, and vaccines ......... 1,835 2.83 21,555 3.54 1,481 4.33 22,230 3.44 
Skin and mucous membrane 
preparations ...................... 3,998 6.17 50,804 8.35 3,033 8.86 52,155 8.08 
Anti-inflammatory agents .......... 1,488 2.30 20,605 3.39 1,409 4.1 1 20,898 3.24 
Spasmolytic agents .................. 1 ,172 1.81 10,234 1.68 809 2.36 10,732 1.66 
Vitamins ........................... 2,198 3.39 21,792 3.58 1,490 4.35 22,754 3.53 
’ Excludes data on Asians, Pacific Islanders. American Indians. and Alaskan Natives. 

‘Based on the pharmacologic-therapeutic classification of the American Society of Hospital Pharmacists; selected categories reproduced with the Society’s permission. 
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Table 10. Number and percent distribution of office visits and drug mentions, num.ber of drug visits and their percent of office visits,cdrug mention rate and-
drug intensity rate, by physician characteristics: United States, 1980 
Office visits Drug visits’ Drug mentions 
Drug Drug 
















All office-based physicians ............... 575,745 100.0 363,489 63.1 679,593 100.0 1.18 1.87 ; 
Specialty 
General and family practice 191,744 33.3 144,478 75.3 279,186 41 .I 1.46 1.93 
Internal medicine ........ 69,481 12.1 53,091 76.4 118,943 17.5 1.71 2.24 
Pediatrics .............. 64,223 11.2 45,575 71.0 72,825 10.7 1.13 1.60 
General surgery ......... 28,315 4.9 28,329 34.8 15,881 2.3 0.56 1.61 
Obstetrics and gynecology 55,123 9.6 23,984 43.5 33,026 4.9 0.60 1.38 
Orthopedic surgery ....... 26,326 4.6 7.787 29.6 11,529 1.7 0.44 1.48 
Cardiovascular disease. ... 6,154 1.1 4.159 67.6 10,162 1.5 1.65 
.2.4~ ;’ I 
Dermatology. ........... 27,857 4.8 21,434 76.9 45.287 6.7 1.63 2.11 
Urology. ............... 8.761 1.5 4,106 46.9 5,265 0.8 0.60 1.28 
Psychiatry. ............. 15,856 2.8 5,706 36.0 9,655 1.4 0.61 1.69 
Neurology. ............. 2,499 0.4 1,848 73.9 3,824 0.6 i .53 2.07 
Ophthalmology. ......... 30,810 5.4 12,666 41 .I 19,281 2.8 0.63 1.52,
Otolaryngology.......... 12,282 2.1 6,269 51.0 9,229 1.4 0.75 1.47 
Region of practice 
Northeast ............... 147,396 25.6 94,525 64.1 172,835 25.4 1.17 1.83 
North Central ............ 139,623 24.3 89,324 64.0 165,899 24.4 1.19 1.86 
South. .................. 182,275 31.7 120.250 66.0 234,866 34.6 1.29 1.95 
West ................... 106,451 18.5 59,389 55.8 105,994 15.6 1 .oo 1.78 
Type of practice 
Solo.................... 313,963 54.5 205,830 65.6 390,716 57.5 1.24 1.90 
Multiole member . 261,783 45.5 157,659 60.2 288,877 42.5 1 .I0 i.83 
Age of physician (M.D.s only) 
Under 45 years. ........... 199.050 36.9 115,863 58.2 207.714 33.2 1.04 1.79 
45-60 years. ............. 251,252 46.6 160,923 64.0 306,001 48.9 1.22 1.90 ,i 
60 years or over ........... 89,291 16.5 59,765 66.9 112,271 17.9 1.26 1.88 
‘An office visit at which one or more drugs was ordered or provided. 
iThe percent of office visits at which one or more drugs were ordered or provided. 
The average number of drugs ordered or provided per office visit. 
4 The average number of drugs ordered or provided per drug visit. 
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Table 1 I. Number and percent distribution of office visits and drug me&ions, number of drug visits and their tiercent of office visits, drug mention rate and 
drug intensity rate, by selected visit characteristics: United States, 1980 
Office visits Drug visits’ Drug mentions 
Drug Drug 
Selected visit characteristic Number 
Percent 










distribution rate3 rate4 
All .................................... 575,745 100.0 363,489 63.1 679.593 100.0 1.18 1.87 
Referral status 
Referred by another physician .............. 25.370 4.4 10.983 43.3 18,958 2.8 0.75 1.73 
Not referred by another physician. .......... 550,375 95.6 352.506 64.0 660,635, 97.2 1.20 1.87 
Patient visit status 
New patient ............................ 85.519 14.9 46.371 54.2 80,380 11.8 0.94 1.73 
Old patient ............................... 490,226 85.1 317,118 64.7 599,213 88.2 1.22 1.89 
Old patient, new problem ............. 130.294 22.6 93,626 71.9 164,279 24.2 1.26 1.75 
Old patient, old problem .............. 359,932 62.5 223,492 62.1 434,934 64.0 1.21 1.95 
Non-drug therapy5 
None .................................. 303.017 52.6 195,028 64.4 356,386 52.4 1.18 1.83 
Physiotherapy .......................... . 29,281 5.1 18,013 61.5 32,923 4.8 1 ..l 2 1.83 
Officesurgery ........................... 

Family planning ......................... 

Psychotherapy/therapeutic listening ......... 

Diet counseling .......................... 

Family/social counseling .................. 






No followup planned ..................... 

Return at specified time ................... 

Return if needed ......................... 

Telephone followup planned ............... 

Referred to another physician. ............. 

Returned to referring physician ............. 






0 minutes (no face-to-face contact with physi­
cian) ................................. 
1-5 minutes ............................ 
6-lominutes ........................... 
11-15 minutes.. ........................ 
16 minutes or more ...................... 
43,089 7.5 20,945 48.6 34.055 5.0 0.79 1.63 
12,828 2.2 7,888 61.5 10,360 1.5 0.81 1.31 
29.024 5.0 15,601 53.8 31,127 4.6 1.07 2.00 
48,886 8.5 39,128 80.0 85.155 12.5 1.74 2.18 
13.148 2.3 8.970 68.2 16,468 2.4 1.27 1.86 
133,425 23.2 90,523 67.8 183.126 26.9 1.37 2.02 
15.618 2.7 5,136 32.9 8,467 1.2 0.54 1.65 
67,442 11.7 34,528 51.2 55,116 8.1 0.82 1.60 
346,414 60.2 225,443 65.1 443.7 19 65.3 1.28 1.97 
131,404 22.8 92.796 70.6 165,113 24.3 1.26 1.78 
19,955 3.5 13.924 69.8 26,266 3.9 1.32 1.89 
15.157 2.6 6,934 45.7 13,123 i.9 0.87 1.89 
3.677 6.6 1,942 52.8 3.699 0.5 1.01 1.90 
13,088 2.3 2.644 20.2 4,617 0.7 0.35 1.75 
1,380 0.2 *453 ‘32.8 *763 l 0.1 ‘0.55 l 1 .68 
13.813 2.4 10,606 76.8 14,868 2.2 1.08 1.40 
71,894 12.5 40,758 56.7 64,169 9.4 0.89 1.57 
175,660 30.5 117,290 66:s 214,321 31.5 1.22 1.83 
157,619 27.4 104,288 66.2 202.437 29.8 1.28 1.94 
156.758 27.2 90,548 57.8 183,798 27.0 1.17 2.03 
‘An office visit at which one or more drugs were ordered or provided. 
pe percent of office visits at which one or more drugs were ordered or provided. 
The average number of drugs ordered or provided per office visit. 
4The average number of drugs ordered or provided per drug visit. 
5May not add to 100.0 since more than one treatment or disposition was possible. 
6Time spent in face-to-face contact between physician and patient. 
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Table 12. Number and percent distribution of drug mentions 	 by entry status, prescription status, Federal control status, and-composition status: ’ 
United States, 1980 
-,,Number 
Percent
Drug dimension of mintions distribution
in thousands ,. 
: . ,  ,a 
Total............................................................................................... 679,593 1 00.0 ,,, 
Entry status : ., 
Genericname.....................................................................,...............~.. 164,464 24.2 
Brandname......................................................................................... 483,587 7.1.2 
Unknown . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31,542 4.6 
Prescription status 
Prescription drug .............. ......................................... . . . . . . . . . . . . . . . . . . . . . . . . 561,228 82.6 
Nonprescription drug ........... ......................................... . . . . . . . . . . . . . . . . . . . . . . . 85,344 12.6 
Unknown .................... ......................................... . . . . . . . . . . . . . . . . . . . . . . . . . 33,021 ‘, 4.9 r:,“‘I.) 
Federal control status 
Controlled by DEA ’ ............ . . . . . ................... ...... . . . . . . . . . . . . . . . . . . . . . . . . . 58,550 8.6 
Schedule II ............... ................... ..... . ......................... 5,763 :0.8 
Schedule Ill .............. ................... ...... ......................... 12,037 I.8 
Schedule IV .............. ................... ...... ......................... 30,305 4.5 
Schedule V ............... ................... ......................... 10,445 1.5 
Uncontrolled ................. ................... ......................... 588,022 86.5 
Unknown.. .................. ................... . . . . . . ......................... 33.02.1 .4.9 
Composition status 
Single-ingredientdrug.................................................................................. 468,752 69.0 
Combinationdrug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 165,798 24.4 
Multivitamins................................:................................................... 13,500 2..d-:’ 
Unknown...................................................................,....................... 31,542 4.6 
’ Drug Enforcement Administration. 
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Table 13. Number Bf mentions and therapeutic use of the generic agents most frequently named by physicians as entry choices: United States, 1980 
_. Number 
Generics most frequently named es entry choices of mentions Therapeutic use 
in thousands 
Allgenericentrychoices.......; ..................................................... 164,464 
Amihophylline .................................................................... 887 
Amoxicillin ....................................................................... 5,506 
Ampicillin .......... . ............................................................. 9,795 
Aspirin .......................................................................... 8,800 
Chorionicgonadotropill ............................................................. 1,568 
Cortisone ........................................................................ 1,100 
Digoxin .......................................................................... 4,801 
Diphtheria tetanus toxoids .......................................................... 1,167 
Diphtheria tetanus toxoids pertussis .................................................. 6.067 
Erythromycin.. ................................................................... 5,363 
Estrogens ....... ..’ ................................................................ 1,043 
FluorouraciL ...................................................................... 1,609 
Hydrochlorothiazide ................................................................ 5,751 
Hydroconisone .................................................................... 1.732 
lnfluenzavintsvaccine ............................................................. 2,225 
Insu~n...........:.: ............................................................. 5,248 
lronpreparations.....-...................................~ ......................... a74 
Liver ............................................................................ 747 
Meprobamate ...................................................................... 945 
Methotrexate ..................................................................... 1,044 
Multivitamins prenatal ................................................................ 2,082 
Nitroglycerin ...................................................................... 3,132 
Penicillin ......................................................................... 9,736 
Phenobarbital ..................................................................... 1,790 
Phentermine ...................................................................... 718 
Pilocarpine ....................................................................... 979 
Poliovaccine ..................................................................... 6,535 
Potassium............,....................................................- ...... 2,161 
Prednisone ....................................................................... 5,879 
Quinidine ......................................................................... 1.107 
Reserpine ......................................................................... 1,170 
Rubella virus vaccine ............................................................... 581 
Salicylicacid ..................................................................... 922 
Tetanustoxoid..........................., ........................................ 1,583 
Tetracyc~ne...............................................................: ...... 9,478 
Thyroid .......................................................................... 3.071 
Tuberculin ........................................................................ 4,488 
Vitamin B-1 2 ..................................................................... 5,813 










































































Table 14. Number of mentions and therapeutic use of the nonprescription drugs most frequently named by physicians as entry chqjces: United States,,.? % 
.,..
Number 
Nonprescription drugs most frequently named as entry choices, with their generic names of mentions, ,,.Therqpeutic use ,,,,’ 
in thousands 
.- . 
All nonprescription entry choices.. . . . . . . . . . . . . . . . . . . . . . . . .a. .  85,344 
1.. ” .,,,’ 
Anusol (bismuth salts, zinc oxide, etc.). ..................... . . . . . . . 652 Skin irritation/inflammation * .‘\: 
Ascriptin (aspirin) ....................................... . . . . . . 1,389 Analgesic, antipyretic ‘,I .’ d 1 
Aspirin .................................................. . . . . . . 8,800 Analgesic, antipyretic ‘_,. ‘: :Z c 
Betadine (povidone-iodine). ................................. . . . . . . . 767 Antiseptic b 1 1” 
Dimetane (brompheniramine). ............................... 
Donnagel (hyosciamine, atropine. etc.). ....................... 
Dramamine (dimenhydrinate) 
. . 
. . . . 
. . . . . 
. . . . 
2,824 
924 
Antihistamine, d&ongestint.; expectorant 
Antidiarrheal ‘,,./ ,.. ( 
................................ . . ...... 825 Motion sickness *. ,’ 
Duofilm (salicylic acid, lactic acid). ........................... . ...... 545 Warts, keratolytic agent : ‘I’ 
Feosol (ferrous sulfate) ..................................... . . ...... 696 Iron deficiency ‘, 
Ferroussulfate ............................................ ...... ...... 834 Iron deficiency 
Gaviscon (aluminum hydroxide, magnesium trisilicate) ........... ...... ...... 443 Antacid 
Insulin.. ................................................ ...... ...... 5,248 Hypoglycemia $’c I :. “xt,i.*: ’ 
Maalox (aluminum hydroxide, magnesium hydroxide) ............ ...... ...... 1,400. Antacid ‘,, .’ 
Materna (prenatal multivitamins) ............................. ...... ...... 1,491 Multivitamins ‘. : .I,’ 
Metamucil (psyllium). ...................................... ...... ...... 1,160 Laxative : * * ..,, 
Mylanta (aluminum hydroxide, magnesium hydroxide). ........... ...... ...... 1,598 Antacid, antiflatulent ,. 1 : : ” I~,, ., 
Mylicon (simethicone). ..................................... . . . . . 619 Antiflatulent .a..: 
Neo-synephrine (phenylephrine) ............................. . . . . 952 Decongestant i 
Niacin (3-pyridinecarboxylic acid) ............................ . . . . . . 491 Vitamin B-complex component .;:. 
Novahistine (d&xtromethorphan, pseudoephedrine). ............. . 904 Antitussive, decongestant, expectorant :’ 
Podophyllum ............................................. ...... ...... 460 Caustic ‘. 
Prenatal vitamins (unspecified). .............................. ....... ...... 2,082 Multivitamins ‘,., ..,. 
Robitussin (guaifenesin, dextromethorphan, phenylpropanolamine). ...... ...... 1,617 Antitussive, decongestant, expectorant 
Salicylicacid ............................................. ...... ...... 776 Antifungal :.,I 
Stresstabs (general multivitamins). ........................... ...... ...... 594 Multivitamins .. : ..,+ / 
Sudafed(pseudoephedrine) ................................. ...... ...... 1,435 Decongestant ~.- : 
Triaminic (pyrilamine, pheniramine, phenylpropanolamine). ....... ...... ...... 953 Antitussive. decongestant, expectorank 
Tylenol (acetaminophen). ................................... ...... 3.815 Analgesic . . I 
Vitamin B-l 2. ............................................ ...... 1.815 Vitamins ’ 
. . .: 
’ 
Table 15. Number of mention’s and therapeutic use of controlled drugs most frequently named by physicians as entG choices: United State& i 980 ” . 
DEA ’ Number 
Controlled drugs most frequently named as entry choices, with their generic names control of mentions Therapeutic use 
schedule in thousands 
Allcontrolledentrychoices..................................................... 58,550 
Ativan (lorazepam) ............................ . . . . . . . IV 1,503 Tranquilizer 
Dalmane (flurazepam). ......................... . . . . IV 2,202 Hypnotic’a$ent 
Dawocet-N (propoxyphene, acetaminophen) ....... . . . . . IV 3,043 Analgesic 
Darvon(propoxyphene) ........................ . . . . . . IV 1,104 Analgesic 
Demerol (meperidine). ......................... . . . . II 879 Analgesic 
Empirin with codeine (aspirin and codeine) ........ . . . Ill 1,687 Analgesic 
Fastin (phentermine). .......................... . . . IV 1 ,012 Appetite suppressant 
Fiorinal (butalbital, aspirin, phenacetin. caffeine). ... . . . . . . . . Ill 1,435 Analgesic, sedative 
lonamin (phentermine). ........................ . . . . . . . . IV 1,108 Appetite suppressant 
Librium (chlordiazepoxide). ..................... . . . . . . . . . . . . . IV 1.343 Anxiety relief 
Limbitrol (chlordiazepoxide, amitriptyline) ......... , . . .  . . . . . . IV 900 Qepression therapy 
Lomotil (diphenoxylate, atropine) ................ . . . . . . . . V 1,610 Antidiarrhea 
Meprobamate ................................ . . IV 945 Trariquilizer; sedative 
Percodan (oxycodone, aspirin). .................. . . . II 1,105 Analgesic 
Phenergan with codeine (promethazine and codeine) . . I . . . . . V 2,783 Expectorant 
Phenobarbital ................................ . . . . IV 1,790 Anticonvulsant, hypnotic;sedative 
Talwin (pentazocine) .......................... 
Tranxene (clorazepate) 
. . . . . . . IV 779 Analgesic 
......................... . . . . . . . . . . IV 2,217 Tranquilizer 
Tylenol with codeine (acetaminophen and codeine) . . . . . . . . . Ill 3,661 Analgesic 
Valium (diazepam) ............................ . . .,.... . . . IV 6,499 Anxiety relief : 
‘Drug Enforcement Administradon. 
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“.’ Table 16. Number bf mentions and therapeutic use of combination drugs meet frequently named by physicians as entry choices: United States, 1980 
Number 
Combination drugs most frequently named as entry choices, with their generic ingredients of mentions Therapeutic use 
in thousands . 
Actifed (triprolidine, pseudoephedrine). .............................................. 

Aldactazide (spironolactone, hydrochlorothiazide). .................................... 

Aldoril (methyldopa, hydrochlorothiazide) ........ _ ................................... 

Bactrim (sulfamethoxazole, trimethoprim). ............................................ 

Combid (isopropamide iodide, prochlorperazine). ..................................... 

Cortisporin (polymixin-8, bacitracin, neomycin, hydrocortisone) ......................... 

Darvocet-N (propoxyphene, acetaminophen) ............................................ 

Dimetapp (brompheniramine, phenylephrine, phenylpronolamine). ....................... 

Donnagel (hyoscyamine, atropine) ................................................. 

Donnatal (hyoscyamine, atropine, hyoscine, phenobarbital). ............................ 

Drixoral (brompheniramine. pseudoephedrine). ........................................ 

Dyazide (triamterene, hydrochlorothiazide). .......................................... 

Empirin with codeine (aspirinand codeine) .......................................... 





Librax (clidinium bromide, chlordiazepoxide)......................................... 
Lomotil (diphenoxylate, atropine) .................................................. 
Lo/ovral (norgestrel, estradiol). .................................................... 
Maalox (aluminum hydroxide, magnesium hydroxide). ................................. 
Maxitrol (dexamethasone, neomycin, polymixin-8) ..................................... 
Mycolog (triamcinolone, neomycin, nystatin). ........................................ 
Mylanta (magnesium hydroxide, aluminum hydroxide) ................................. 
Naldecon (phenylephrine, phenylpropanolamine, chlorpheniramine). ..................... 
Neosporin (polymixin-8, neomycin) ................................................. 
Norgesic (orphenadrine, aspirin, caffeine, phenacetin) ................................. 
Novahistine (dextromethorphan, guaifenesin, etc.) .................................... 
Ornade (chlorpheniramine, phenylpropanolamine, isopropamide iodide) .................. 
Ortho-novum (norethindrone, estradiol) ............................................. 
Ovral (norgestrel, estradiol) ....................................................... 
Parafon forte (chlorzoxazone, acetaminophen). ....................................... 
Percodan (aspirin, oxycodone) ..................... . ................................ 
Phenergan with codeine (promethazine and codeine). ................................. 
Rondec (pseudoephedrine, carbinoxamine maleate) .................................... 
Septra (sulfamethoxazole, trimethoprim) ............................................ 
Ser-Ap-Es (reserpine, hydralazine, hydrochlorothiazide) ................................ 
Triaminic (pyrilamine maleate, pheniramine, phenylpropanolamine) ...................... 

Triavil (perphenazine, amitriptyline) ................................................ 

Tuss-Omade (chlorpheniramine, phenylpropanolamine, isopropamide iodide) .............. 

Tylenol with codeine (acetaminophen and codeine) .................................... 







2,943 Urinary infections, otitis media, pneumonitis 











2.520 Sedative, antispasmodic 





1,687 Analgesic, antipyretic 

1,435 Analgesic, sedative 

952 Aplanation tonometiy 









1,162 Ocular inflammation 

1,649 Anti-inflammatory (skin) 

1,598 Antacid, antiflatulent 

1,166 Hayfever, sinus, congestion 









1,697 Oral contraceptive 

956 Oral contraceptive 







1,241 Decongestant, antitussive 





997 Antitussive, decongestant, expectorant 
1,305 Tranquilizer, antidepressant 
929 Antitussive, decongestant 
3,661 Analgesic 
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Table 17. Number and 
Selected therapeutic categories’ 
All categories ............... 
Antihistamine drugs. ......... 
Anti-infective agents ......... 
Antibiotics ............. 
Antineoplastic agents ........ 
Autonomic drugs ............ 
Blood formation and 
coagulation. .............. 
Cardiovascular drugs ......... 
Cardiac drugs ........... 
Hypotensive agents. ..... 
Vasodilating agents. ..... 




Sedatives and hypnotics . . 
Electrolytic, caloric, and water 
balance .................. 
Diuretics. .............. 
Expectorants and cough 
preparations. ............. 
Eye, ear, nose, and throat 
preparations. ............. 
Gastrointestinal drugs. ....... 
Hormones and synthetic 
substances ............... 
Adrenals ............... 
Serums, toxoids, and vaccines. 
Skin and mucous membrane 
preparations. ............. 
Spasmolytic agents .......... 
Vitamins ................... 
percent of drug mentions according to entry status, prescription status. Federal control status, and 
by selected therapeutic categories: United States, 1980 
Number Entry status Prescription status federal control stark 
of drug 
Non- Un­mentions Generic Brand Prescription 
prescription 
Controlled 
controlledin thousands name name drug 
drug drug drug 
679,593 24.2 71.2 82.6 
43,939 1.3 73.8 67.6 
104,898 40.4 58.9 98.8 
90,081 46.3 52.8 99.1 
5,371 61.9 37.8 99.8 
25,237 5.5 93.9 92.0 
8,312 24.2 75.3 64.4 
64,463 19.1 80.5 99.0 
26,331 25.9 74.1 98.4 
22,633 9.4 89.5 98.9 
14,646 23.0 77.0 100.0 
110,706 17.0 81.8 83.3 
57,800 20.9 79.1 70.4 
16,395 10.3 89.3 99.6 
25,036 13.7 85.7 99.4 
51,956 19.1 79.9 97.1 
42,834 15.0 83.8 98.7 
18,899 *3.2 95.1 67.5 
26,076 11.8 85.8 80.8 
24,140 4.1 92.6 36.8 
55,843 37.1 61.5 98.6 
18,312 43.8 56.2 00.0 
23,711 80.3 14.5 94.8 
55.188 10.9 86.2 72.1 
11,541 16.6 83.4 9512 
24,244 52.3 38.9 37.4 
Percent of drug mentions 
12.6 8.6 88.5 




7.2 ‘0.9 98.3 
35.1 99.5 




15.5 41.5 57.3 
29.6 27.2 72.7 
7.2 92.3 
88.7 10.7 
1 .s 99.0 
*0.2 98.8 
30.8 44.0 54.3 
16.8 97.6 





*4.8 ‘4.7 95.3 
53.8 91.2 
composition status, 
Composition stqtus -, 
Single- Combina­






99.8 ,., -, 
52.2 47.1 


















70.5 ’ ; 29.5 
39.5 52.7 
‘Based on the pharmacologic-therapeutic classification of the American Society of Hospital Pharmacists: selected categories reproduced with the Society’s permission. 
.’ 
‘The totals in this column contain a residual for which entry status, prescription status. Federal control status, and composition status are unknown. 

‘Includes multivitamina (with 13.500.000 mentions). 
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Table 18. Number and percent of drug mentions according to entry status, prescription status, Federal control status, and composition status, 
by selected principal diagnoses: United States, 1980 
[Drug information,is.limited to drugs ordered or provided for principal diagnosis only (Patient Record, item 11 a)] 
. 5: Number Entry srarus Prescription status Federal control status 
Composition status 
of drug 




in thousands2 name name drug . drug 
drug 
.drug drug drug3 
Percent of drug mentions 
All principal diagnoses . . . . . . . . . 581,231 24.8 70.3 82.4 12.4 8.6 86.5 68.2 26.8 
lnfecticus and parasitic 
diseases . . . . . . . . . . . . . . . . . . 21:007 25.7 70.1 75.1 19.7 4.4 90.4 70.8 25.0 
Neoplasms . . . . . . . . . . . . . , . . . . 9,546 40.7 56.2 ‘90.4 l 6.4 *7.3 89.5 83.5 13.4 
Endocrine, nutritional, and 
metabolic diseases and 
immunity disorders . . . . . . . . * 33.240 34.9 61.9 82.0 14.6 16.5 80.1 86.2 10.6 
Diseases of endocrine 
glands................ 16,523 35.7 62.7 74.2 23.9 l 3.5 94.5 88.7 9.7 
Obesity and other 
.hyperalimentation _ . . . . . 13,554 37.8 56.8 90.1 ‘4.5 34.5 60.4 84.1 10.5 
Diseases of blood and blood- , . . 
forming organs.. . . . . . . . . . . . 3.457 46.4 50.5 74.8 22.1 *4.6 92.3 72.5 24.5 
Mental disorders . . . . . . _ . . . . . 18,324 13.1 84.4 90.7 .6.6 30.9 66.5 80.7 16.8 
Nonpsychotic disorders. . _ . 13,925 1.2.2 84.7 8849 7.9 36.6 6b. 1 77.3 19.6 
Diseases of nervous system and 
sense organs . . . . . . . :. . . . . . 48,964 20.6 76.5 85.6 11.4 5.0 92.1 61.9 35.2 
Diseases of central nervous 
system . . . . . . . . . . . . . . . 5,413 15.9 79.8 90.2 *5.5 23.2 72.6 71.8 23.9 
Disorders of eye and 
adnexa . . . . . . . . . . . . . . . 15,855 15.9 80.5 87.0 9.5 *0.4 96.1 67.8 28.5 
Ofitis media (suppurative 
and unspecified). . . A . . . . 17,398 26.7 71 .o 87.3 . ‘10.3 +3.4 94.2 57.8 39.i 
Diseasesof circulatorysystem. . . 84,213 21 .o 77.0 90.6 7.3 4.0 93.8 79.5 18.4 
‘Essential hypertension . . . 38,463 17.4 80.7 93.7 4.4 4.2 93.9 73.2 24.9 
,lschemic heart disease . . . . 20,599 24.5 74.1 92.6 6.0 *3.7 94.9 90.8 7.5 
Diseases of respiratory system. . . 116,302 25.2 66.8 79.4 12.5 7.9 84.0 63.6 28.3 
Acute upper respiratory 
infections . . . . . . . _ , . . . 26,300 23.1 73.8 79.9 17.0 10.0 86.9 59.0 37.8 
Asthma . . . . . ., . . . . . . . . . 10,594 18.5 66.0 78.7 . 5.7 ‘4.1 80.3 69.8 14.6 
Diseases of digestive system . . . 24,646 15.4 80.4 70.3 25.4 13.2 82.6 55.8 40.0. 
Diseases of genitourinary 
system . . . . . . . . . . . . . . . . . 26,658 16.2 80.2 91.0 5.4 5.7 90.7 63.2 33.3 
Diseases of male genital 
organs. . . . . . . . . . . . . . . 3.023 18.6 79.6 93.8 l 4.4 ‘4.4 93.8 62.8 35.4 
Diseases of female genital 
. organs.. . _ . . . . . . . . . _ 12,550 18.9 77.2 89.5 6.6 ‘6.2 89.8 65.0 31.1 
Diseases of skin and 
subcutaneous tissue . . . . . . . 53,416 25.4 71.5 83.6 12.2 l 1.1 94.7 78.9 i 8.0 .
Diseases of musculoskeletal 
system . . . . . . . . . . . . . . . . . . . 37,544 20.0 77.9 85.0 13.0 13.1 84.9 77.3 20.6 
Arthropathies.. . ;. . . . . 14,447 24.0 74.0 82.3 15.7 8.4 89.6 84.7 13.3’ 
Symptoms, signs, and ill-defined 
conditions. . . . . . . . . . . . . . . . . 17.093 16.2 79.3 79.5 16.0 15.9 79.5 66.6 28.9 
Injury and poisoning . . . . . _ . . . . 27.264 20.6 68.3 77.1 11.7 17.7 71.2 58.6 30.3 
Normal pregnancy.. , . : . . . . . . 9,908 26.8 65.2 41.6 50.4 *0.3 91.6 17.8 74.2 
Health supervision of infant 
or child.. . . . . . . . . . . . . . . . . 15,219 77.6 18.4 .92:2 l 3.8 ‘0.4 95.6 54.3 41.7 
’ Based on the International Classification of Diseases, 9tb Revision, Clinical Modification (ICD-g-CM). 
2The totals in this column contain a residual for which entry status, prescription status. Federal control status and composition status are unknown. 
31ncludes multivitamins (with 11.705.000 mentions). 
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Table IS. Number and percent of drug mentions according to entry status, prescription status, Federal control status, and composition status, 
by patient characteristics: United States, 1980 
Number EnOy status Prescription status Federal control status Composition status 
















Percent of drug mentions , 
All patients .................. 679,593 24.2 71.2 82.6 12.6 8.6 86.5 69.0 , 26.4 
Age 
Under 5 years ................ 65,167 36.5 59.8 81.8 14.4 4.3 91.9 58.4 37.9 
5-I 4 years. ................. 50,476 27.2 62.8 76.6 13.3 4.8 85.1 61 .O 29.0 
15-24 years. ................ 75,213 25.8 67.9 74.1 15:3 6.9 86.5 60.4 33.3 
25-34 years ................. 83,802 22.4 71.6 79.7 14.0 12.4 81.4 62.9 31.1 
35-44 years ................. 64,324 21 .o 74.6 83.9 11.2 13.3 81.9 70.6 h,‘,s .a,.,25..9 
45-54 years. ................ 78,351 21.5 73.6 84.8 10.2 11.5 83.4 72.8 / 22.3 
55-64 years ................. 97,221 21.7 74.8 85.1 11.1 9.1 87.2 75.2 21.2 
65-74 years. ................ 98,924 22.0 75.3 87.5 11.5 7.3 99.8 76.1 21.1,: 
75 years and over ............ 66,115 23.5 74.2 84.3 13.0 6.2 91 .I 76.8 29.8 b 
SW i 
Female ..................... 413,570 23.6 71.9 82.7 12.7 9.1 86.2 68.3 27.2 
Male ....................... 266,023 25.2 69.9 82.4 12.4 7.8 87.0 70.0 ‘25.1 
Sex and age 
Female 
Under I5 years ............... 54,723 33.4 61 .O 80.4 13.9 4.8 83.5 60.4 34.1 ,‘( 
15-24 years. ................ 49,823 24.0 69.7 77.3 16.3 6.8 86.8 56.5 37.2.. 
25-44 years. ................ 97,947 21.5 73.2 81.4 13.0 12.6 81.8 65.3 29.5 
45-64 years ................. 106,333 21.3 74.5 85.4 10.2 11 .o 84.7 73.5 22.2 
65 years and over ............ 104.745 22.5 75.0 84.9 12.4 7.4 89.8 75.6 21.9 
Male 
Under I5 years ............... 60,920 31.6 61.1 78.7 14.0 4.2 88.4 58.8 33.9 
15-24 years. ................ 25,391 29.3 64.3 73.7 13.3 7.1 86.0 68.0 25.7 
25-44 years. ................ 50,179 22.3 72.4 81.9 12.4 13.2 81.2 68.2 26.5 ’ 
45-64 years. ................ 69,239 22.2 73.9 84.4 11.4 9.0 86.8 75.2 20.9!:, 
65 years and over ............ 60,294 22.7 74.6 85.6 Il.5 5.8 91.3 77.9 ‘IS.4 
Race 
White ...................... 608,346 24.2 70.9 82.5 12.4 8.5 86.4 69.1 26.6 
Black ....................... 64,808 23.7 73.5 83.6 13.5 9.9 87.2 67.8 29.4 
Other3 ...................... 6,439 25.9 70.5 79.3 17.1 9.6 86.8 66.1 30.3 
Ethnicity 
Hispanic .................... 34,239 22.4 72.3 81.2 13.1 10.6 83.7 66.0 28.7 
Not Hispanic ................ 645,354 24.3 71.1 82.7 12.5 8.5 86.7 69.1 26.3 
.‘The totals in this column contain a residual for which entry status, prescription status. Federaicontrol status, and composition status are unknown: 
. .21ncludes multivitamins (with 13.500.000 mentions). 
‘Asian, Pacific Islander. American Indian. or Alaskan Native. 
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,Table 20. Number and percent of drug mentions according to entry status, prescription status, Federal control status, and composition status, 
by physiCian characteristics: United States, 1980 
Number Entry status Prescription status 




















Percent of drug mentions 
All office-based physicians. .... 679.593 24.2 71.2 82.6 12.8 8.6 86.5 69.0 28.4 
Specialty 
General and family practice. .... 279,186 24.3 71.2 83.3 12.0 10.9 84.5 68.3 27.2 
Internal medicine. ............ 118,943 24.3 72.8 84.6 12.5 8.2 88.9 78.2 18.9 
Pediatrics ................... 72,825 34.9 57.8 79.5 13.1 ,, 4.6 88.0 58.9 33.8 
General surgery .............. 15,881 17.2 80.5 83.1 14.4 16.7 81.7 66.3 31.4 
. :. .. 33,026 17.6’ 77.8 75.9 19.3 5.2 90.0 47.5 47.8 
Orthopedic surgery ........... 11,529 11.4 86.0 88.6 8.8 22.5 74.8 69.9 27.5 
Cardiovascular disease ........ 10.162 25.9 71.3 87.9 9.3 ’ ‘6.2 91.0 81.8 15.4 
Dermatology. ................ 45,287 24.2 71.4 79.1 15.1 *0.5 93.6 76.5 19.1 
Urology ..................... 5,265 14.b 83.6 93.0 l 4.5, *5.5 92.0 68.3 29.3 
Psychiatry ................... 9,655 15.9 82.6 92.9 ‘5.3 23.8 74.4 86.9 11.6 
Neurology. .................. 3,824 *15.4 83.7 89.4 ‘9.7 *14.9 84.2 84.3 ‘14.7 
Ophthalmology. .............. 19,281 15.8 80.4 85.5 10.7 *0.8 95.4 68.0 28.2 
Otolaryngology. .............. 9.229 14.2 81.2 82.9 . 11.9 ‘4.0 SO.8 54.9 40.5 
Region of practice 
Northeast ................... 172,835 29.1 64.0 80.2 12.7 7.3 85.6 69.4 23.8 
North Central ................ 165,899 23.4 73.3 82.8 13.5 6.9 89.5 68.9 27.7 
South.. .................... 234,866 20.2 75.4 82.9 12.6 10.8 84.8 67.8 27.8 
West ....................... 105,994 26.3 70.0 85.3 10.6 8.7 87.3 71.0 25.4 
Type of practice 
Solo . . . . . . . . . . . . . . . . . . . . . . . 390,716 24.4 70.1 82.2 12.6 9.1 85.8 68.4 25.7 
Multiple member.. . . . . . . . . .. . . 288,877 23.3 71.7 83:0 12.5 8.0 87.5 68.4 27.3 
Age of physician (M.D.s only) 
Under 45 years. .............. 207,714 23.3 72.7. 82.5 13.2 6.3 89.4 68.9 27.1 
4576O.years. .. :. ............ 306.001 24.6 70.8 82.3 13.0 8.9 86.4 68.8 26.7 
60 years or over .............. 112,271 24.6 70.2 82.9 ’ 11.5 10.3 84.1 68.4 25.3 
‘The totals in this column contain a residual for w ’hich entry status, prescription status, Federal control status, and composition status are unknown. 
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Appendix I. Technical notes 
This report is based on data collected during 1980 
in the National Ambulatory Medical Care Survey 
(NAMCS), an annual sample survey of officsbased 
physicians conducted by the Division of Health Care 
Statistics of the National Center for Health Statistics. 
Statistical design 
Scope of the survey 
The target population of NAMCS encompasses 
office visits made within the conterminous United States 
by ambulatory patients to nonfederally employed physi­
cians who are principally engagedin offrcsbased patient 
care practice, but not in the specialties of anesthesi­
ology, pathology, or radiology. Telephone contacts and 
nonoffice visits are excluded. 
Sample design 
The NAMCS utilizes a multistage probability de-
sign that involves probability samples of primary sam­
pling units (PSU’s), physician practices within PSU’s, 
and patient visits within physician practices. The first-
stage sample of 87 PSU’s was selected by the National 
Opinion Research Center (NORC) of the University of 
Chicago, the organization responsible for NAMCS 
field and data processing operations under contract to 
NCHS. A PSU is a county, a group of adjacent counties, 
or a standard metropolitan statistical area (SMSA). A 
modified probability-proportional-to-size procedure 
using separate sampling frames for SMSA’s and for 
nonmetropolitan counties was used to select the sample 
PSU’s. After sorting and stratifying by size, region, and 
demographic characteristics of the PSU’s, each frame 
was divided into sequential zones of 1 million residents, 
then a random number was drawn to determine which 
PSU came into the sample from each zone. 
The second stage consisted of a probability sample 
of practicing physicians selected from the masterfiles 
maintained by the American Medical Association 
(AMA). and the American Osteopathic Association 
(AOAj as of December 3 1,1979, who met the follow­
ing criteria: 
l Office-based, as defined by AMA and AOA. 
l Principally engaged in patient care activities. 
l Nonfederally employed. 
l 	 Not in the specialties of anesthesiology, pathology, 
or radiology. 
The 1980 NAMCS physician universeincluded 2 17,500 
doctors of medicine and 10,058 doctors of osteopathy 
(see table I).
Within each PSU, all eligible physicians were ar- . 
ranged by nine specialty groups: general and family 
practice, internal medicine, pediatrics, other medical 
specialties, general surgery, obstetrics and gynecology, 
other surgical specialties, psychiatry, and all other spe­
cialties. Then, within each PSU, a systematic random 
sample of physicians was selected so that the overall 
probability of selecting any physician in the United 
States was approximately constant. 
During 1980 the NAMCS physician sample in­
cluded 2,959 physicians. Sample physicians were 
screenedat the time of the survey to ensurethat they met 
the aforementioned criteria; 611 physicians did not 
meet all the criteria and were, therefore, ruled out of 
scope(ineligible) for the study. The most common reasons 
for being out of scope were that the physician was re-
tired, deceased, or employed in teaching, research, or 
administration. Of the 2,348 inscope (eligible) physi­
cians, 1,869 (79.6 percent) participated in the study. 
The physician sample size and response data by physi­
cian specialty are shown in table I.. 
The final stage was the selection of patient visits 
within the annual practices of the sample physicians. 
This stage involved two steps. First, the total physician 
sample was divided into 52 random subsamples of ap
proximately equal size, and each subsample was ran­
domly assignedto 1 of the 52 weeks in the survey year. 
Of the participating physicians, 249 saw no patients 
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Table I. Distribution of physicians in the universe (AMA and AOA)’ and in the National Ambulaton/ Medical Care Survey sample, by physician’s specialty: 





ofPhysician specialty Universe total total respondents 
All specialties.. 
General and family practice. 
Medical specialties.. . 
Internal medicine. . . . 
Pediatrics . . . . 
Other medical specialties 
Surgical specialties . . 
General surgery , 
Obstetrics and gynecology 
Other surgical specialties.. 
Other specialties. . . . . . 
scoae 
. . 227,558 2,959 611 2,348 479 1,869 
...... . . 53,147 676 155 521 133 388 
...... ...... . . 66,692 864 172 692 138 554 
...... ...... . . 35,199 458 92 366 85 281 
...... ...... 16,043 204’ 46 158 19 139 
...... ...... 1545.0 202 34 168 34 134 
...... ...... . 77,625 1,002 131 871 164 707 
...... ...... . 21,486 269 39 230 . 60 170 
...... ...... . 18,246 247 36 211 27 184 
...... ...... . 37,893 486 56 430 77 353 














. . . 
...... ...... . 30,094 417 153 264 44 220 
Psychiatry. . . . . . . . . ...... ...... . 16,662 223 55 168 22 146 
Other specialties. . . . . . . . . . . . . 13,432 194 98 96 22 ‘. 74 
1 AMA = American Medical Association, AOA = American Osteopathic Association. 
during their assignedreporting period because of vaca­
tions, illnesses, or other reasons for being temporarily 
out of office-based practice. Second, a systematic ran­
dom sample of visits was selected by the physician 
during the assignedweek. The sampling rate varied for 
this final step from a 100 percent sample for very small 
practices to a 20 percent sample for very large practices. 
The method by which the sampling rate was determined 
is described later in this appendix.‘During 1980,46,08 1~ 
usable Patient Record forms were completed by physi­
cians participating in NAMCS. 
Data collection and processing 
Field procedures 
Both mail and telephone contacts were used to en-
list sample physicians for NAMCS. Initially, physi­
cians were sent introductory letters from the Director of 
NCHS. When appropriate, a letter from the physician’s 
specialty organization endorsing the survey and urging 
participation was enclosed with the NCHS letter. Ap 
proximately 2 weeks prior to the physician’s assigned 
reporting period, a field representative telephoned the 
physician to explain briefly the study and arrange an 
appointment for a personal interview. Physicians who 
did not initially respond were usually recontacted via 
telephone or special explanatory letter and requestedto 
reconsider participation in the study. 
During the personal interview the field representa­
tive determined the physician’s eligibility for the study, 
obtained his or her cooperation, delivered survey mate-
rials with verbal and printed instructions, and assigneda 
predetermined Monday-Sunday reporting period. A 
short induction interview concerning basic practice 
characteristics, such as type of practice and expected
number of offrce visits, was conducted. Office staff who 
were to assistwith data collection were invited to attend 
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the instructional.sessionor were offered separateinstruc­
tional sessions. 
Before the beginning and again during the week as-
signed for data collection, the field representativetele­
phoned the sample physician to answer,questions that 
might have arisen and to ensure that survey procedures, 
were going smoothly. At the end of the reporting week, 
the participatingphysicianmailed the completed survey
materials to the field representative, who edited the 
forms for completeness before transmitting them .for 
central data processing. At this stage problems of mis­
sing or incomplete data were resolved by telephone 
followup by the field representative to the sample physi­
cian; if no problems were found, field procedures were 
considered complete regarding the sample physician’s 
participation in NAMCS. 
Data collection 
The actual data collection for NAMCS was carried 
out by the physician, assistedby office staff when pas: 
sible. Two data collection forms were employed by the 
physiciamthe Patient Log and the Patient Record form 
(figure 1). The Patient Log, a sequential listing of pa­
tients seen in the physician’s office during his or her 
assigned reporting week, served as the sampling frame 
to indicate the office visits for which data were to be 
recorded. A perforation between the patient’s name and 
patient visit information permitted the physician to de-
tach and retain the listing of patients, thus protecting the 
confidentiality of the physician’s patients. 
Based on the physician’s estimate of the expected 
number of office visits and expected number of days in 
practice, eachphy&ian was assigneda patient-sampling 
rate. The patient-sampling rates were designed so that 
about 30 Patient Record forms would be completed by 
each physician during the assigned reporting week. 
Physicians expecting 10 or fewer visits each day re-
corded data for all visits, those expecting more than 10 
visits per day recorded data for every second, third, or 
fifth visit, based on the predetermined sampling interval. 
These patient-sampling procedures minimized the phy­
sician’s data collection workload and maintained ap 
proximately equal reporting levels among sample 
physicians regardlessof practice size. For physicians re-
cording data for every second,third, or fifth patient visit, 
a random start was provided on the first page of the 
Patient Log so that predesignatedsample visits recorded. 
on each succeeding page of the Patient Log provided a 
systematic random sample of patient visits during the 
reporting period. 
Data processing 
In addition to followups for missing and inconsist­
ent data made by the field staff, numerous clerical edits 
were performed on data received for central data process­
ing. These manual procedures proved quite efficient, 
reducing item nonresponse rates to 2 percent or less for 
most data items. 
The patient’s problem or reason for visit (item 6 of 
the Patient Record form) was coded according to the 
Reason for Visit Classzscation forAmbulatory Care 
(RVC). Diagnostic information (item 9 of the Patient 
Record form) was coded according to the International 
Classz2cation ofDiseases, 9th Revision, ClinicaEMod­
ification (ICD-g-CM). A maximum of three entries 
were coded from each of these items. Prior to coding, 
Patient Record forms were grouped into batches with 
approximately 650 Patient Record forms per batch. 
Quality control for the medical coding operation in­
volved a two-way 5 percent independent verification 
procedure. Error rates were defined as the number of 
incorrectly coded entries divided by the total number of 
coded entries. The estimated error rates for the medical 
coding operation were 1.9 percent for item 6 and 2.8 
percent for item 9. A dependent procedure was used to 
review and adjudicate all records in batches with ex­
cessive error rates. This procedure further reduced the 
estimated error rates to 1.8 percent for item 6 and 2.5 
percent for item 9. 
The NAMCS medication data (item 11 of the Pa­
tient Record form) was classified and coded according 
to a schemedeveloped at NCHS based on the American 
Society of Hospital Pharmacists’Drug Product Infor­
mation File. A detailed description of the development
of the new drug coding scheme and of the NAMCS drug 
data processing procedures are contained in Vital and 
Health Statistics Series ~-NO. 90. A two-way 100 
percent independent verification procedure was used to 
control the medication coding operation. All Patient 
Record forms with differences between drug coders or 
with illegible drug entries were reviewed and adjudi­
cated at NCHS. 
Information from the Induction Interview and Pa­
tient Record forms was keypunched with 100 percent 
verification and converted to computer tape. At this 
point, extensive computer consistency and edit checks 
were performed to ensure complete and accurate data. 
Incomplete items were imputed by assigning a value 
from a randomly selected Patient Record form with 
similar characteristics; patient sex and age, physician 
specialty, and broad diagnostic categories were used as 
the basis for these imputations. 
Estim.ation procedures 
Statistics from the 1980 NAMCS were-derived by a 
multistage estimation procedure which produces essen­
tially unbiased national estimates and has three basic 
components: (1) inflation by reciprocals of the prob­
abilities of selection, (2) adjustment for nonresponse, 
and (3) a ratio adjustment to fixed totals. A description 
of each component follows. 
Inflation by reciprocals of 
probabilities of selection 
Becausethe survey utilized a three-stage sample de-
sign, three probabilities of selection existed: (1) the 
probability of selecting the PSU, (2) the probability of 
selecting the physician within the PSU, and (3) the 
probability of selecting a patient visit within the physi­
cian’s practice. The last probability was defined as the 
exact number of office visits during the physician’s 
assigned reporting week divided by the number of Pa­
tient Record forms completed. All weekly estimates 
were inflated by a factor of 52 to derive annual esti­
mates. 
Adjustment for nonresponse 
Estimates from NAMCS data were adjusted to ac­
count for sample physicians who did not participate in 
the study. This adjustment was calculated in order to 
minimize the impact of response on final estimates by 
imputing to nonresponding physicians the practice char­
acteristics of similar responding physicians. For this 
purpose, physicians were judged similar if they had the 
same specialty designation and practiced in the same 
PSU. 
Ratio adjustment to fmed totals 
A poststratification adjustment was made within 
each of nine physician specialty groups. The ratio ad­
justment was a multiplication factor which had as its 
numerator the number of physicians in the universe in 
each physician specialty group and as its denominator 
the estimated number of physicians in that particular 
specialty group. The numerator was based on figures
obtained from the AMA and AOA masterfiles, and the 
denominator was based on data from the sample. 
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Reliability of estimates 
As in any survey, results are subject to both sam­
pling and nonsampling errors. Nonsampling errors in­
clude reporting and processing errors, as well as biases 
due to nonresponseor incomplete response.The magni­
tude ,of the nonsampling errors cannot be computed. 
However, these errors were kept to a minimum by pro­
cedures built into the survey’s operation. Careful atten­
tion and extensive pretesting were given to the phrasing 
of the questions, terms, and definitions employed to 
eliminate ambiguities and encourage uniformity of re-
porting. The steps taken to reduce bias in the data are 
discussed in the sections on field procedures and data 
collection. Quality control procedures and consistency 
and edit checks discussedin the data processing section 
reduced errors in data coding and processing. However, 
because survey results are subject to sampling and non-
sampling errors, the total error will be larger than the 
error due to sampling variability alone. 
Because the statistics presented’in this report are 
basedon a sample,they differ somewhat from the figures 
that would be obtained if a complete census had been 
taken using the same forms, definitions, instructions, 
and procedures. However, the probability design of 
NAMCS permits the calculation of sampling errors. 
The standard error is primarily a measure of sampling
qariability that occurs by chance because only a sample 
rather than the entire population is surveyed. The stand­
ard error, as calculated in this report, also reflects part of 
the variation that arises in the measurement process. It 
does not include estimates of any systematic biases that 
may be in the data. The chances are about 68 out of 100’ 
that an estimate from the sample would differ from a 
complete census by less than the standard error. The 
chances are about 95 out of 100 that the difference 
would be less than twice the standard error, and about 
99 out of 100 that .it would be less than 2% times as 
large.
The relative standard error of an estimate is ob 
tained by dividing the standard error by the estimate 
itself and is expressed as a percent of the estimate. For 
this report, an asterisk (*) precedes any estimate with 
more than a 30 percent relative standard error. 
Estimates of sampling variability were calculated 
using the method of half-samplereplication. This method 
yields overall variability through observation of varia­
bility among random subsamples of the total sample. A 
description of the development and evaluation of the 
replication technique for error estimation has been pub 
lished. Approximate relative standard errors for ag­
gregate estimates are presented in figures I and II. To 
derive error estimatesthat would be applicable to a wide 
variety of statistics and could be prepared at moderate 
cost, several approximations were required. As a result, 
the relative standard errors shown in figures I and II 
should be interpreted as approximate rather than exact 
for any specific estimate. Directions for determining 
approximate relative standard errors follow. 
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Estimates of aggregates 
Approximate relative standard errors (in percent), 
for aggregatestatistics are presented in figures I and II.: 
Figure I presents approximate relative standard errors. 
for estimates of office visits, while figure II presents 
approximate relative standard errors for estimates of 
drug mentions. In each figure, curve A represents the 
relative standard errors appropriate for estimates based 
on all physician specialties, and curve B represents
relative standard errors appropriate for estimates based 
on an individual physician specialty. It 
Alternatively, relative standard errors for aggregate
estimates may be calculated directly using the following 
formulae where x is the aggregateof interest in thousands. 
For visit estimates based on all physician specialties, 
36.36433
RSE(x) = 0.00164987 + x. * 100.0 
For visit estimates based on an individual physician 
specialty, 
36.97024. ioo o
RSE(x) = 0.00434821 + 
X 
For drug mention estimates based on all physician spe-.
cialties, 
71.2643.1 . 1oo o
RSE(x) = 0.003 16979 + 
X 
For drug mention estimates based on an individual 
physician specialty, 
RSE(x) = 0.00827256 + 69.54527 . ‘1oo o 
X 
Estimates of percentages 
Approximate relative standard errors (in percent) 
for estimates of percentages may be calculated from 
figures I and II as follows. From the appropriate curve 
obtain the relative standard error of the numerator and 
denominator of the percentage. Square each of the rela­
tive standard errors, subtract the resulting value for the 
denominator from the resulting value’for the numerator,’ 
and extract the square root. This approximation is valid 
if the relative standard error of the denominator is less, 
than .05 percent or if the relative standard errors of the 
numerator and denominator are both less than . 10 per-
cent. 
Alternatively, relative standard errors for percent-
ages may be calculated directly using the following
formulae wherep is the percent of interest and x is the 
base of the percentage in thousands. For visit percent-, 
age based on all physician specialties, 

















Size of estimate (in thousands) 
E ramp/e ofuse ofchart: An estimate of 20 million office visits to general surgeons (read from scale at bottom of chart) has a relative standard error of 7.9 percent (read from curve E on scale at leftoi fchart) 
01 a standard error of 1,580,OOO office visits (7.9 percent of 20 million office visits). 
Figure I. Approximate relative standard errors for estimated numbers of office visits based on all physician specialties (A) and individual specialties (5). 1980 
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Size of estimate(in thousands) 
Example of use of chart; An estimate of 60 mill ion drug mentions to general practitioners (read on scale at bottom of chart) has a relative standard error of 9.7 percent (read from curve B on scale EIt left 
of chart) or a standard error of 5.820.000 drug mentions (9.7 percent of 60 mill ion drug mentions). 
:Figure II. -Approximate relative standard errors’for estimated numbers of drug mentions based on all physician specialties (A) and individual specialties (B), 1980 
National Ambulatory Medical Care Survey 
For visit percentages based on an individual physician 
specialty, 
For drug mention percentages based on all physician 
specialties, 
RWP) =p=yTJ. loo*o 
For drug mention percentages based on an individual 
physician specialty, 
-pyyJ. lo*.oRSE(p) -
Estimates of rates where the numerator 
is not a subclass of the denominator 
Approximate relative standard errors for rates in 
which the denominator is the total United States popu­
lation or one or more of the age-sex-race groups of the 
total population are equivalent to the relative standard 
error of the numerator that can be obtained from figures 
I and II. 
Estimates of differences 
between two statistics 
The relative standard errors shown in this appendix 
are not directly applicable to differences between two 
sample estimates. The standard error of a difference is 
approximately the square root of the sum of squares of 
each standard error considered separately. This for­
mula represents the standard error quite accurately for 
the difference between separate and uncorrelated char­
acteristics, although it is only a rough approximation in 
most other cases. 
Tests of significance 
In this report, the determination of statistical in­
ference is based on the t-test with a critical value of 1.96 
(0.05 level of significance). Terms relating to differ­
ences, such as “higher, ” “less,” and so forth, indicate 
that the differences are statistically significant. Terms 
such as “similar” or “no difference” mean that no sta­
tistical significance exists between the estimates being 
compared. A lack of comment regarding the difference 
between any two estimates does not mean that the dif­
ference was tested and found to be not significant 
Rounding of numbers 
Estimates presentedin this report have been rounded 
to the nearest thousand. For this reason detailed figures 
within tables do not always add to totals. Rates and 
percents were calculated on the basis of the original, 
unrounded figures and may not necessarily agree pre­
cisely with percents calculated from rounded data. 
Systematic bias 
No formal attempt was undertaken to determine or 
measure systematic bias in the NAMCS data. But it 
should be noted that there are several factors affecting 
the data which indicate that these data under-represent 
the total number of office visits. 
1. 	 Although physicians who participated in NAMCS 
did a thorough and conscientious job in keeping the 
Patient Log, postsurvey interviews with partici­
pating physicians indicate that a small number of 
patient visits may have been accidentally omitted 
from the Patient Log. While this number is quite 
small, such omissions would result in an undercov­
erage of offrce visits.. 
The same postsurvey interviews indicate that 
the inclusion of patient visits which did not actually 
occur was infrequent and would have a negligible 
effect on survey estimates. 
2. 	 As previously stated, the universe for the 1980 
NAMCS included all nonfederal, of&e-based, pa­
tient-care physicians in the AMA and AOA, mas­
terfiles. The NAMCS was designed to provide sta­
tistically unbiased estimates of office visits to this 
designated population. Not included in the uni­
verse were physicians classified in such categories 
as federally employed, hospital-based, research, 
teaching, administration, or other nonpatient care 
activity. Consequently, any ambulatory patient
visits to physicians not in the NAMCS universe, an 
included in NAMCS estimates. 
In an attempt to measure the number of office 
visits to physicians not in the NAMCS universe, an 
NAMCS Complement Survey was conducted in 
1980. This study involved a sample of approxi­
mately 2,000 physicians selected from among the 
226,000 physicians in the AMA and AOA master-
files who were not eligible (inscope) for the 1980 
NAMCS. Details of the Complement Survey 
methodology and results are forthcoming. Prelimi­
nary results indicate that about 17 percent of the 
Complement Survey universe ‘saw some ambula­
tory patients in an office setting. An estimated 69 
million office visits were made to these physicians 
in 1980. This indicates that the total number of 
office visits to all physicians during 1980 was about 
645 million (69 million plus 576 million). 
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Appendix I I. Definition of 
terms 
Terms relating to the survey 
Ofice.-Premises identified by the physician as 
locations for his or her ambulatory practice. The re­
sponsibility over time for patient care and professional 
services rendered there generally resides with the indi­
vidual physician rather than with any institution. 
Ambulatory patient.-An individual seeking per­
sonal health services, who is neither bedridden nor cur­
rently admitted to any health care institution on the 
premises. 
Physician.-Classified as either: 
l 	 Inscope.-All duly licensed doctors of medicine 
and doctors of osteopathy currently in practice who 
spend some time caring for ambulatory patients at 
an office location. 
l 	 Out ofscope.-Those physicians who treat patients 
only indirectly, including physicians in the special-
ties of anesthesiology, pathology, and radiology, 
and the following physicians: 
Physicians who are federally employed includ­
ing those physicians in military service. 
Physicians who treat patients only in an insti­
tutional setting, for example, patients in nursing 
homes and hospitals. 
Physicians employed full time by an industry or 
institution and having no private practice, for 
example, physicians who work for the Veterans 
Administration, the Ford Motor Company, and 
so forth. 
Physicians who spend no time seeing ambula­
tory patients, for example, physicians who only 
teach, are engaged in research, or are retired. 
Patients.-Classified as either: 
l 	 Inscope.-All patients seen by the physician or a 
staff member in his or her office(s). 
0 	 Out of scope.-Patients seen by the physician in a 
hospital, nursing home, or other extended care insti­
tution, or the patient’s home. Note: If the physician 
has a private office, meeting the definition of “of­
fice,” located in a hospital, the ambulatory patients 
seen there are considered inscope. The following 
types of patients are considered out of scope: ’ ’ 
l 	 Patients seen by the physician in an institution, 
including outpatient clinics of hospitals,for whom 
the institution has primary responsibility over 
time. 
l 	 Patients who contact and receive advice from 
the physician via telephone. .’ 
l 	 Patients who come to the office only to leave a 
specimen, pick up insurance forms, or pay.their 
bills. 2. . . \A’ 
l 	 Patients who come to the office only to pick up
medications previously prescribed.by the phy­
sician. .. . 
Visit.-A direct, .personal exchange between an 
ambulatory patient and a physician ora member of his 
or her office staff for the purpose of seeking care’and 
rendering health services. >‘. 
Physician specialty. -Principal specialty,.including 
general practice, as designated by the physician at the 
time of the survey. Those physicians for Whom a spei 
cialty was not obtained were assigned the principal 
specialty recorded in the physician masterfiles main­
tained by the American Medical Association or the .American Osteopathic Association. 
Region ofpractice location.-The four geographic 
regions, excluding Alaska and Hawaii, that correspond 
to those used by the U.S. Bureau of the Census:. ., 
Region States included ., 
Northeast . . . . Connecticut, Maine, Massachusetts, New 
Hampshire, New Jersey, New York, Penn-
Sylvania, Rhode Island, Vermont 1’. 
North Central. . Illinois, Indiana, Iowa, Kansas, Michigan, 
Minnesota, Missouri, Nebraska, North Da­
kota, Ohio, South Dakot’a, Wiiconsi,; -
South. . . . Alabama, Arkansas, Delaware, .District of 
Columbia, Florida, Georgia, Kentucky, Loui­
. 
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Region-Con. Stares included-Con. 
siana, Maryland, Mississippi, North Caro­
lina, Oklahoma, South Carolina, Tennes­
see, Texas, Virginia, West Virginia 
West . . . . . . . . . . Arizona, California, Colorado, Idaho, Mon­
tana, Nevada, New Mexico, Oregon, Utah, 
Washington, Wyoming 
Metropolitan status ofpractice location.-A phy­
sician’s practice is classified by its location in a metro­
politan or nonmetropolitan area. Metropolitan areas 
are standardmetropolitan statistical areas( SMSA’s) as 
defined by the U.S. Ofice of Management and Budget. 
The definition of an individual SMSA involves two 
considerations: first, a city or cities of specified popula­
tion which constitute the central city and identify the 
county in which it is located as the central county; 
second, economic and social relationships with “con­
tiguous” counties which are metropolitan in character 
so that the periphery of the specific metropolitan area 
may be determined. SMSA’s may cross State lines. In 
New England, SMSA’s consist of cities and towns 
rather than counties. 
Terms relating to the . 
Patient Record form 
Age.-The age calculated from date of birth was the 
age at last birthday on the date of visit. 
CoZor or race.-On the Patient Record form, color 
or race ‘includes four categories: White, Black, Asian/ 
Pacific Islander, and American Indian/Alaskan Native. 
The physician was instructed to mark the category which 
in his ‘or her judgment was most appropriate for the 
patient based on.observation or prior knowledge. The 
. following definitions were provided to the .physician: 
White.-Asperson having origins in any of the or­
iginal peoples of Europe, North Africa, or the Middle 
East. 
Black. -A person having origins in any of the black 
racial groups of Africa. 
Asia$P&fic Islander.-A person having’origins 
in any ofthe original peoples ofthe Far East, South-
east Asia, the Indian subcontinent, or the Pacific 
Islands. This area includes, for example, China, 
India, Japan, Korea, the Philippine Islands, and 
Samoa. 
American Indian/Alaskan Native.-A person hav­
ing origin: in any of the original peoples ofNorth 
America, and who maintains cultural identification 
through tribal affiliation or community recognition. 
Ethnicity.-The physician was instructed to mark 
the category which in his or herjudgment was most appro­
priate. The following definitions were provided. 
a 	 Hispanic origin.-A person of Mexican, Puerto 
Rican, Cuban, Central or South American, or other 
Spanish culture or origin, regardless of race. 
l 	 Not Hispanic. -Any person who is not of Hispanic 
origin. .! 
l 	 Patient’s complaint(s), symptom(s), or other rea­
son(s) for this visit(inpatient’s own words).-The 
patient’s principal problem, complaint, symptom, 
or other reason for this visit as expressed by the 
patient. Physicians were instructed to record key 
words or phrases verbatim to the extent possible, 
listing that problem first which, in the physician’s 
judgment, was most responsible for the patient’s 
visit. 
Major reason for this v&it-The physician was 
instructed to check one major reason for the patient’s 
visit. 
l 	 Acuteproblem: A visit primarily for a condition or 
illness having a relatively sudden or recent onset 
(within three months of the visit). 
l 	 Chronic problem, routine: A visit primarily to re­
ceive regular care or examination for a pre-existing 
chronic condition or illness (onset of condition was 
three months or more before the visit). 
l 	 Chronicproblem, flareup: A visit primarily to re­
ceive care for a sudden exacerbation Iof a pre-exist­
ing chronic condition or illness. 
l 	 Post surgery and/orpost injury: A visit primarily 
for followup care of injuries or for care required 
following surgery, for example, removal of sutures 
or cast. 
l 	 Non-illness care (routine prenatal, general exam, 
well baby, etc.): General health maintenance ex­
aminations and routine periodic examinations of 
presumably healthy persons, both children and 
adults. Includes prenatal and postnatal care,: an­
nual physicals, well child examinations, and insur­
ance examinations. 
Diagnostic services this visit.-Physicians were 
instructed to check any of the following services that 
were ordered or provided during the current visit:’ 
Limited history and/or exam: History or physical 
examination which is limited to a specific body site 
or system or which is concerned primarily with the 
patient’s chief complaint, for example, pelvic ex­
amination or eye examination. 
General history and/or exam: History or physical
examination of a comprehensive nature, including 
all or most body systems. 
Pap test: Papanicolaou test, self-explanatory. 
Clinical lab test: One or more laboratory proce­
dures or tests, including examination ofblood, urine, 
sputum, smears, exudates, transudates, feces, and 
gastric content, and including chemistry, serology,
bacteriology, and pregnancy test. Excludes Pap 
test. 
X-ray: Any single or multiple X-ray examination 
for diagnostic or screeningpurposes. Excludes radi­
ation therapy. 
BZood pressure check: Self-explanatory. 
EKG: Electrocardiogram, self-explanatory. 
I%ion test: Visual acuity test. 
Endoscopy: Examination of the interior of any body
cavity, except ear, nose, and throat, by means of an 
endoscope. 
Mental status exam: Any formal, clinical evalua­
tion designed to assess the mental ‘or emotional 
status of the patient. 
Other: All other diagnostic services ordered or pro­
vided which are not included in the preceding cate­
gories. 
Principal diagnosis. -The physician’s diagnosis of 
the patient’s principal problem, complaint, or symptom. 
In the event of multiple diagnoses, the physician was 
instructed to list them in order of decreasingimportance. 
The term “principal” refers to the first-listed diagnosis. 
The diagnosis represents the physician’s best judgment 
at the time of the visit and may be tentative, provisional, 
or definitive. 
Other significant current diagnoses.-The diag­
nosis of any other condition known to exist for the 
patient at the time of the visit. Other diagnoses may or 
may not be related to the patient’s reason for visit. 
Have you seen patient before?-“Seen before” 
means provided care for at any time in the past. The 
second part of item 10 refers to the patient’s current 
episode of illness. 
Medication therapy this visit. -The physician was 
instructed to list, using brand or generic names, all 
medications, including drugs, vitamins, hormones, oint­
ments, and suppositories, ordered, injected, admin­
istered, or provided this visit. Included are prescription 
and non-prescription drugs, vaccinations, immunization 
and desensitization agents.Also included are drugs and 
medications which were ordered or provided prior to the 
visit and which the physician instructed or expected the 
patient to continue taking. Medications for the principal 
diagnosis are listed in item 11 a; and all other drugs in 
item 11b. 
Nonmedication therapy.-Physicians were in­
structed to check any of the following services that were 
ordered or provided during the current visit: 
l Physiotherapy: Any form of physical therapy or­
dered or provided, including any treatment using 
heat, light, sound, or physical pressure or move­
ment, for example, ultrasonic, ultraviolet, infrared, 
whirlpool, diathermy, cold, and manipulative ther­
apy. 
l 	 Ofice surgery: Any surgical procedure performed in 
the office this visit, including suture of wounds, 
reduction of fractures, application or removal of 
casts, incision and draining of abscesses,applica­
tion of supportive materials for fractures and sprains,
and irrigations, aspirations, dilations, and excisions. 
0 	 Family planfling: Services, counseling, or advice 
that might enable patients to determine the number 
and spacing of their children. Includes both contra­
ception and infertility services. 
0 	 Psychotherapy and)/or therapeutic listening All 
treatments designed to produce a mental or emo 
tional response through suggestion, persuasion, :re-
education, reassurance, or support, including psy­
chological counseling, hypnosis, psychoanalysis, 
and transactional therapy. 
0 	 Diet counseling: Instructions, ‘recommendations, 
or advice regarding diet or dietary habits. 
0 	 Family an&or social counseling: Advice regarding 
problems of family relationship, including marital 
or parent-child problems, or social problems, in­
cluding economical, educational, occupational, 
legal, or social adjustment difficulties. 
0 	 Medicalcounseling: Instructions and recommenda­
tions regarding any health problem, including ad-
vice or counsel about a change of habit or behavior. 
Physicians were instructed to check this category 
only if medical counseling was a significant part of 
the treatment. Excludes family planning, diet coun­
seling, and family or social counseling. 
0 	 Other: Treatments or non-medication therapies or­
dered or provided which are not listed or included in 
the above categories. 
Waspatientreferredfor this visit by anotherphysi­
cian?-Referrals are any visits that are made at the 
advice or direction of a physician other than the one 
being visited. The interest is in referrals for the current 
visit and not in referrals for any prior visit. 
Disposition this visit.-Eight categories are pro­
vided to describe the physician’s disposition ofthe case. 
The physician was instructed to check as many of the 
categories as apply: 
No followup planned: No return visit or telephone 
contact was scheduled for the patient’s problem. 
Return atspeciJied time: Patient was told to schedule 
an appointment or was instructed to return at a 
particular time. 
Return if needed P.R. N.: No future appointment 
was made, but the patient was instructed to make an 
appointment with the physician if the patient con­
sidered it necessary. 
Telephone followup planned: Patient was in­
structed to telephone the physician on a particular
day to report either on his or her progress, or if the 
need arose. 
Referred to otherphysician: Patient was instructed to 
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consult or seek care from another physician. The 
patient may or may not return to this physician at a 
later date. 
l 	 Returned to referring physician: Patient was re­
ferred to this physician and was not instructed to 
consult again with the physician who referred him or 
her. 
l 	 Admit to hospitak Patient was instructed that fur­
ther care or treatment would be provided in a hos­
pital:No further oflice visits were expected prior to 
hospital admission. 
l 	 Other: Any other disposition of the case not in­
cluded in the above categories. 
Duration of this visit.-Duration includes time the 
physician spent with the patient, not including time the 
patient spent waiting to see the physician, time the 
patient spent receiving care from someone other than 
the physician without the presence of the physician, and 
time the physician spent in reviewing records, test re­
sults, etc. If the patient was provided care by a member 
of the physician’s staff but did not see the physician
during the visit, the duration of visit was recorded as 
zero minutes. 
Vital and Health Statistics series descriptions
I 
SERIES 1. Programs and Collection Procedures.-Reports describing SERIES 14. Data on Health Resources: Manpower and Facilities-
the general programs of the National Centerfor Health Statis- Statistics on the numbers, geographic distribution, and char-
tics and its offices and divisions and the data collection acteristics of health resources including physicians. dentists. 
methods used. They also include definitions and other material nurses, other health occupations, hospitals, nursing homes. 
necessary for understanding the data. and outpatient facilities. 
SERIES 2. Data Evaluation and Methods Research.-Studies of new SERIES 15. Data From Special Surveys.-Statistics on health and health-
statistical methodology including experimental tests of new related topics collected in special surveys that are not a part of 
survey methods, studies of vital statistics collection methods, the continuing data systems of the National Center for Health 
new analytical techniques, objective evaluations of reliability Statistics. 
of collected data, and contributions to statistical theory. SERIES 20. Data on Mortality.-Various statistics on mortality other than 
SERIES 3. Analytical and Epidemiological Studies.-Reports presenting as included in regular annual or monthly reports. Special 
analytical or interpretive studies based on vital and health sta- analyses by cause of death, age, and other demographic 
tistics, carrying the analysisfurtherthan the expositorytypesof variables; geographic and time series analyses; and statistics 
reports in the other series. on characteristics of deaths not available from the vital records 
SERIES 4. Documents and Committee Reports.-Final reports of major based on sample surveys of those records. 
committees concerned with vital and health statistics and SERIES 21. Data on Natality, Marriage, and Divorce.-Various statistics 
documents such as recommended model vital registration laws on natality, marriage, and divorce other than as included in 
and revised birth and death certificates. regular annual or monthly reports. Special analyses by demo-
SERIES 10. 	 Data From the National Health Interview Survey.-Statistics graphicvariables; geographicand timeseriesanalyses:studies 
on illness, accidental injuries, disability, use of hospital, of fertility: and statistics on characteristics of births not 
medical, dental, and other services, and other health-related available from the vital records based on sample surveys of 

topics, all based on data collected in the continuing national those records. 

household interview survey. SERIES 22. Data From the National Monthly and Natality Surveys.-

SERIES 11. 	 Data From the National Health Examination Survey and the Discontinued in 1975. Reports from these sample surveys 
from direct examination, testing, and measurement of national respectively. 
samples of the civilian noninstitutionalized population provide SERIES 23. Data From the National Survey of Family Growth.-Statis-
the basis for (1) estimates of the medically defined prevalence tics on fertility, family formation and dissolution, family 
_ of specific diseases in the United States and the distributions planning, and related maternal and infant health topics derived 
of the population with respect to physical, physiological, and from a periodic survey of a nationwide probability sample of 
psychological characteristics and (2) analysis of relationships ever-married women 15-44.years of age. 
among the various measurements without reference to an 
explicit finite universe of persons. 
National Health and Nutrition Examination Survey.-Data based on vital records are included in Series 20 and 21. 
SERIES 12. 	 Data From the Institutionalized Population Surveys.-Dis­
continued in 1975. Reports from these surveys are included in 
Series 13. For a list of titles of reports published in these series, write to: 
SERIES 13. 	 Data on Health Resources Utilization.-Statistics on the utili- Scientific and Technical Information Branch 
zation of health manpower and facilities providing long-term National Center for Health Statistics 
care, ambulatory care, hospital care, and family planning Public Health Service 
services. Hyattsville. Md. 20782 
